This application is a Division of U.S. patent application Ser. No. 13/209,573, filed Aug. 15, 2011, now U.S. Pat. No. 8,956,859, issued Feb. 17, 2015, which is a non-provisional of, and claims benefit of priority from, U.S. Provisional Patent Application Ser. No. 61/373,375, filed Aug. 13, 2010, the entirety of which are expressly incorporated herein by reference.
This invention is related to the field of diagnostic methods and kits relating to immune responses of a host, including humans.
Citation or identification of any reference herein, or any section of this application shall not be construed as an admission that such reference is available as prior art to the present application. The disclosures of each of these publications are hereby incorporated by reference in their entirety in this application, and shall be treated as if the entirety thereof forms a part of this application.
In the United States, conventional influenza types A or B viral epidemics can cause illness in 10% to 20% of people and are associated with an average of 36,000 deaths and an estimated 120,000-200,000 hospitalizations per year (estimates vary to do complications of pneumonia). In the advent of a highly pathogenic avian type influenza pandemic, the potential for severe morbidity and mortality will be substantially higher, and will occur during a time where the healthcare system is overburden. Many people will receive prior vaccination. During conventional epidemics, those receiving a vaccine do so with the presumption that 1) the vaccination will be successful and 2) that the vaccine matches the emerging pathogenic strain. Prior to, and during, a pandemic of highly pathogenic avian influenza or other influenza strain, those two assumptions may be inaccurate, yet, at the present time, there is no readily available means for people to determine if these immunization criteria have been met.
Currently established serological methods for detection of antibodies to influenza are necessary to conduct clinical trials of influenza vaccination, but are technical in nature, not accessible to the general public, and do not compare results for different antigens that would allow determination of which vaccine may have been successful when one or more vaccines has been administered (Cheng et al., 2008, Serologic and genetic characterization analysis of a highly pathogenic influenza virus (H5N1) isolated from an infected man in Shenzhen, J. Med. Virol. 80: 1058-1064; Katz et al., 1999, Antibody response in individuals infected with avian influenza A (H5N1) virus and detection of anti-H5 antibody among household and social contacts. J. Infect. Dis. 180: 1763-1770; Rowe et al., 1999, detection of antibody to avian influenza A (H5N1) virus in human serum using a combination of serologic assays, J. Clin. Microbiol. 37: 937-943).
Such methods determine the immune response, or seroconversion, in the host, which are specific antibody responses to vaccination or post viral infection, and should not be confused with diagnostics that determine the presence of the physical virus particle during infection such as described by Zambon and Ellis, 2001 (Molecular methods for diagnosis of influenza International Congress Series 1219: 267-273).
Following influenza vaccination performed in mid-1997 a study was performed by de Jong et al., (2001, Antibody responses in elderly to influenza vaccination in case of an antigenic mismatch, International Congress Series 1219: 707-711) wherein sera were obtained from vaccinees of various ages, including residents of nursing homes over 60 years of age. As a surrogate marker for induction of protection by influenza vaccination, they studied the haemagglutination inhibition (HI) antibody response of the vaccinees to vaccine and epidemic strains of the three (sub)types A(H3N2), A(H1N1), and B. Statistical methods included the paired t-test, the McNemar c2-test, the one-way ANOVA, the Pearson c2-test, and a “minimum-maximum” analysis, newly developed by Dr G. Lüchters from Bonn. In accordance with usual practice, the “50% protective threshold” of HI antibodies was set at 1:40 (Periera et al., 1972, Prevalence of antibody to current influenza viruses and effect of vaccination on antibody response. British Medical Journal 4:701-703).
In the influenza season of 1997/1998, a major antigenic mismatch of the H3N2 vaccine component occurred. They found that the vigor of immune responses declined at higher ages. Sera from influenza vaccinees was further used to assess the magnitude of this effect in case of an antigenic mismatch. At advanced age, the homologous antibody response was lowered, starting above 60 years. In addition, they found that the cross-reactivity of the formed antibodies to the drifted field virus decreased with age, starting above 70 years. They concluded that effect of ageing on the induction of “protective” titres (≧40) of HI antibodies against an emerging deviant strain can be severe, and that in the 1997/1998 season, in those above 80 years of age, the percentage of vaccinees acquiring such titres against the major epidemic H3N2 virus was only about 15%.
In the study by Keren et al., 2005 (Failure of influenza vaccination in the aged, J. Med. Virol. 25: 85-89), they found that in a cohort of 127 nursing home residents aged 60-98 years vaccinated during the winter of 1985-86 with the A-Chile 1/83 (c), A-Philippines 2/82 (p), and B-USSR (B) commercial influenza vaccines, that before vaccination 40%, 23%, and 69% were susceptible to influenza Ac, Ap, and B, respectively [hemagglutinin inhibition (H.I.) titer <1:40] and that one month following initial vaccination, 32 patients [25%] remained unprotected against two or all three vaccine strains. The unprotected patients were revaccinated with the same influenza vaccine and followed up. At five months 11%, 19%, and 23% of the initial cohort were still unprotected against Ac, Ap, and B strains, respectively. They conclude that two conventional influenza vaccines administered one month apart leave unprotected 30% of healthy elderly people who are initial influenza vaccine failures.
Physicians have long believed that the elderly often fail to generate a sufficient immune response for protection when given a standard seasonal flu shot, as illustrated in the studies by de Jong et al., 2001 and Keren et al., 2005 described above. About 90 percent of the estimated 36,000 people who die from flu-related causes in the United States each year are 65 and older, and account for an estimated 120,000 hospitalizations. Although fewer children die from influenza, infection results in an additional 20,000 hospitalizations per year, with a total up to 200,000 resulting from all influenza infections. Unfortunately, of those who are vaccinated with conventional vaccines, there is no convention regarding determination of the extent to which the vaccination was successful. The fact that the vaccine may not be antigenically matched to the emergent seasonal vaccine further compromises the overall protective effect on the population. Despite the obvious “leap-of-faith” in being vaccinated without determining effectiveness, there has been no apparent movement toward developing a diagnostic test that would inform a patient whether they were adequately protected.
Highly pathogenic H5N1 avian influenza presents a number of similar complications as conventional influenza as well as new challenges in effectively protecting individuals within a population. First, the vaccines for H5N1 have not been subjected to an epidemiological challenge for effectiveness (i.e., an actual pandemic); surrogate markers such as the level of anti-influenza antibodies are used to gauge effectiveness. It is generally accepted that an antibody level of 1:40 (higher numbers indicate better protection) is required to give 50% protection for a standard influenza. A number of vaccine makers have increased production of conventional-type vaccine for H5N1, and a number of biotechnology companies have introduced new approaches to generating novel vaccines and have shown the ability to generate anti-H5N1 antibodies, including the use of virus-like particles (Pusko et al., 2010, Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus, Vaccine, 28:4771-4776) or influenza proteins produced in tobacco plants (Lico et al., 2009, Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice. Vaccine, 27:5069-76). However, given the highly pathogenic nature of the H5N1 avian influenza (50-80% mortality), an antibody level of 40 may not be effective at all, at least on its own. Thus, a remarkably novel situation exists in terms of the number of different vaccine manufacturers and types of vaccines that may be available for H5N1 for which the ramifications have not been explored. This situation will also be complicated by differences in the antigens used to prepare the vaccine and their match to the emerging pathogen or pathogens. In countries where multiple types of vaccines are available, it seems probable that people will question the efficacy of individual vaccine types, which would require diagnostic testing in order to determine; a situation that has not been previously recognized and for which no solution has been proposed. The potential ineffectiveness of a single vaccine may lead many to seek a second vaccination using the same or an alternative vaccine type. While it would seem desirable to proceed to multiple vaccinations without testing, only through testing will the individuals within the population know if and/or when a vaccine or set of vaccines has been effective for them personally and will the medical field know which vaccines and/or combination of vaccines are effective within a population. The consequence of an unsuccessful vaccination and infection by H5N1 may be death, dramatically skewing the cost-benefit ratio analysis. Furthermore, in the advent of a shortage, the availability of a second vaccine for those already receiving an initial injection may not be justifiable without a diagnostic test indicating its necessity, even if the test were more expensive than the vaccine itself.
The present invention uses novel methods and provides a diagnostic kit for determining successful vaccination for influenza and other infectious diseases. Unlike conventional diagnosis of successful vaccination, the present invention provides simultaneous testing against multiple antigens containing “fingerprint” signatures that allows not only the determination of successful vaccination, but the ability to determine which vaccine was successful in the event multiple vaccines are administered to the same host. The diagnostic influenza vaccination test also provides information as to the strain(s) of influenza for which vaccination has been successful, as well as subtypes, immune escape variants, and neurominadase resistant strains. The diagnostic device and/or kit are particularly useful for highly pathogenic influenza, such as the H1N1 “swine” and H5N1 “avian” flu strains.
Influenza and vaccines for the prevention of influenza and the associated immune responses are used as a non-limiting illustrative example. The present invention comprises an in vitro diagnostic test that can be informative of the following:
It is therefore an object to provide a system and method for testing for presence of an antibodies to an antigen from a host, comprising providing: a reactant layer, into which are absorbed the antigen, an anti-host immunoglobulin IgM antibody bound to a ligand, and a detector comprising a non-host anti-antigen IgG antibody conjugated to colloidal particles; a test strip, in fluid communication with the reactant layer at a portion thereof, to which is immobilized a ligand binding agent at a test area and anti-non-host IgG immobilized at a control area, the test area being spaced more proximate to the reactant layer than the control area; and a sample well.
A serum specimen from a host is placed in the sample well, and host antigen-specific antibodies in the specimen are permitted to selectively form a quaternary complex with the detector/antigen/IgM complex. The quaternary complex migrates through the test strip and is captured at the test area by the immobilized ligand binding agent. Detector/antigen/IgM complex unbound to antigen-specific host antibodies migrate through the test strip, past the test area, and are captured at the control area by the immobilized anti-IgG. A presence of the host antigen-specific antibodies is detected by an indication at the test area and validity of the test is ensured by an indication at the control area. The colloidal particles are preferably readily detectable, though other types of detectors may also be used in substitution for the colloidal particles.
It is a further object to provide a testing system and method for presence of an antibodies to a particular antigen from a host, comprising: providing a reactant layer, having a the particular antigen, an anti-host immunoglobulin IgM antibody bound to a ligand, and a non-host anti-antigen IgG antibody conjugated to a detector; forming a complex by adding serum containing host antibodies to the particular antigen, wherein the host antibodies and the IgG bind the particular antigen, and the IgM binds the host antibodies; migrating the complex on a strip toward a first region having an immobilized ligand binding agent which binds and ceases migration of the IgM antibody and any complexes including the IgM antibody; migrating residual of the complex past the first region to a second region having immobilized anti-non-host IgG immobilized at a control area, which binds the non-host IgG antibody and any complexes including the non-host IgG antibody, wherein, if the host antibodies have a high affinity for the antigen and are present in sufficient quantity, a complex comprising the antigen, the host antibodies, and the anti-host IgM antibodies and the non-host anti-antigen IgG and detector are retained in the first region for detection based on the presence of the detector, and if the host antibodies have a low affinity for the antigen or are not present in sufficient quantity, a complex comprising the antigen, the non-host anti-antigen IgG and detector, will migrate past the first region and b retained at the second region for detection based on the presence of the detector.
The ligand is preferably biotin and the ligand binding agent is preferably strepavidin.
The colloidal particles are preferably gold particles.
The concentrations of antigen, anti-host immunoglobulin IgM antibody bound to the ligand, the detector, immobilized ligand binding agent and immobilized anti-IgG are provided, based on calibration with pooled sera from successfully immunized hosts, to produce a positive indication at an IgM Index value of at least 1.1 of an IgM Capture ELISA device and a negative indication results below an IgM Index value of 1.1.
The antigen is, for example, an influenza hemaggutinin (e.g., hemagglutinin or neuraminidase), which may be produced by a bacterium. The antigen may comprise a gene product of an inserted gene in a genetically engineered bacterium. The antigen may be an influenza hemagglutinin produced by a genetically engineered bacterium, a non-glycosylated protein produced by a bacteria corresponding to a glycosylated protein produced by a virus during mammalian infection, produced in insect cells, a glycosylated antigen produced in an insect cell/baculovirus method, produced in an insect cell and has (or is absent) a hexahistidine tag, correspond to an influenza hemagglutinin antigen if an influenza strain which causes human disease, correspond to an influenza neuraminidase antigen of an influenza strain which causes human disease, an epitope peptide of a pathogenic influenza, and/or the epitope peptide may comprise an epitope hemagglutinin peptide modified to be covalently bound to a non-hemaggutinin epitope peptide.
The anti-host immunoglobulin IgM antibody bound to a ligand may comprise biotinylated goat-antihuman IgM.
The non-host anti-antigen IgG antibody may comprise mouse monoclonal IgG anti-antigen antibody.
The anti-IgG immobilized at the control area may comprise rabbit antimouse IgG-Fc. The mouse monoclonal IgG anti-antigen antibody may be conjugated onto colloidal gold particles.
The antigen, the anti-host immunoglobulin IgM antibody bound to a ligand, and the detector may be dispensed as at least one solution on the reactant layer and subsequently lyophilized.
The reactant layer may comprise a polyester pad. The test strip may comprise a nitrocellulose membrane. The test strip may comprise an elongated strip, on which the reactant layer is situated on one side, and the test area and control area are sequentially disposed distant from the test strip. The sample well may be provided on top of the reactant layer, and between the reactant layer and the test strip is disposed at least one flow control layer. The test system may further comprise an absorbent pad in fluid communication with the test strip disposed on an opposite side of the control area from the reactant layer, wherein the absorbent pad induces a bulk fluid flow from the reactant layer to the absorbent pad.
The method may further comprise vaccinating the host with the antigen, and/or vaccinating the host with multiple antigens concurrently.
The test may further comprise a plurality of control areas, each associated with response indicative of absence of antibodies to a different antigen, wherein for each different antigen, a corresponding anti-non-host IgG antibody having respectively different conserved portions, conjugated to colloidal particles is provided, and at each respective control area, a corresponding anti-non-host IgG specific for the respectively different conserved portions is immobilized.
The present invention provides, according to various embodiments, compositions and methods for diagnosis of successful vaccination that can determine infectious subtypes for which an individual is vaccinated, and provides a means to distinguish between immune responses in vaccinees that have received more than one type of vaccine. The types of infectious diseases may generally include prions, viruses, bacteria, protozoans (protists), fungi and helminthes (Mandell, Bennett and Dolin 2010, Principles and Practices of Infectious Diseases, 7th Edition, Elsiever Publishers, 4320 pages). A particularly useful application is for assessment of influenza vaccination.
For reasons of clarity, the detailed description is divided into the following subsections: 1) infectious types and subtypes, 2) antigens, 3) epitopes, 4) posttranslational modifications of antigens and epitopes, and 5) antibody-based tests.
5.1. Infectious Types and Subtypes.
There are three types of influenza viruses Influenza A, B, and C. Influenza type A viruses are divided into subtypes based on two proteins on the surface of the virus. These proteins are termed hemagglutinin (H) and neuraminidase (N). Influenza A viruses are divided into subtypes based on these two proteins. There are 16 different hemagglutinin subtypes H1, H2, H3, H4, H6, H7, H8, H9 H10 H11 H12, H13, H14, H15 or H16 and 9 different neuraminidase subtypes N1 N2 N3 N4 N5 N6 N7 N8 or N9, all of which have been found among influenza A viruses in wild birds. Wild birds are the primary natural reservoir for all subtypes of influenza A viruses and are thought to be the source of influenza A viruses in all other animals, such as pigs, giving rise to “swine flu” strains. The current subtypes of influenza A viruses found in people are A(H1N1) and A(H3N2). Influenza B virus is not divided into subtypes. Influenza A genome contains 11 genes on eight pieces of RNA, encoding for 11 proteins; hemagglutinin, neuraminidase (NA), nucleoprotein (NP), M1, M2, NS1, NS2 (NEP), PA, PB1, PB1-F2 and PB2 (Ghedin et al., 2005, Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 437: 1162-1166).
5.2. Antigens.
The antigens are those from the infectious disease for which one or more vaccines has been prepared, having identifiable sequences that may contain specific signature sequences. The signature sequences may comprise one or more amino acid sequence variations within an antigenic portion of the antigen, including subtype differences, immune escape forms, or drug resistant forms. The differences may include posttranslational modifications of the antigen. In the case of influenza A, the antigens are H1, H2, H3, H4, H6, H7, H8, H9 H10 H11 H12, H13, H14, H15 or H16 and 9 different neuraminidase subtypes N1 N2 N3 N4 N5 N6 N7 N8 or N9, as well as the nucleoprotein (NP), M1, M2, NS1, NS2 (NEP), PA, PB1, PB1-F2 and PB2.
5.3. Epitopes.
Epitope mapping, the determination of epitopes, uses processes known to those skilled in the arts and may include any methods known such as protease digestion/mass spectroscopy, spot membrane, phage peptide panning, monoclonal antibodies, hydrogen/deuterium exchange and/or crystallography in order to determine distinctive signature or fingerprint antigens (Morris (ed) Epitope Mapping Protocols, Humana Press, 1996; Joys and Schodel 1991. Infect. Immune. 59: 3330-3332; Hioe et al., 1990 J. Virol. 64: 6246-6251; Kaverin et al. 2002, J. Gen. Virol. 83: 2497-2505; Hulse et al. 2004, J. Virol. 78: 9954-9964; Kaverin et al. 2007, J. Virol. 81:12911-12917; Garcia et al., 2004, Hydrogen/deuterium exchange mass spectrosmetry for investigating protein-ligand interactions, ASSAY and Drug Development Technologies 2: 81-91; Kaverin et al., 2007, Epitope mapping of the hemagglutininin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies, J. Virol. 81: 12911-12917; Hoffman et al., 2005, Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines, PNAS 102: 12915-12920). T-cell epitope determination (Walden, 1996, Current Opinion in Immunology 8: 68-74) and computer programs such as Predict7 (Carmenes et al. 1989 Biochem. Biophys. Res. Comm 159: 687-693) and Pepitope (Mayrose et al., 2007. Bioinformatics 23: 3244-3246) or PepScan (Carter 1994, Epitope mapping of a protein using the Geysen (PEPSCAN) procedure. Methods Mol Biol. 1994; 36:207-23; Philpott et al., 1989, Neutralizing epitopes of the H5 hemagglutinin from a virulent avian influenza virus and their relationship to pathogenicity, J. Virol. 63: 3453-3458). Similar forms or homologous eiptopes can be determined as described by Deem and Pan, 2009 (The epitope regions of H1-subtype influenza A with application to vaccine efficacy, Protein Engineering and Selection 22: 543-546) by aligning sequences using amino acid sequence alignment algorithms such as ClustalW or by alignment of three-dimensional structure using “homology modeling” (Nayeem et al., 2006, A comparative study of available software for high-accuracy homology modeling: From sequence alignments to structural models, Protein Sci 15: 808-824).
A fingerprint or signature antigen, and/or epitope within the antigen, is one that is present in one form of a vaccine, and different by at least one or more amino acids, or absent in another form, and such, that antibodies produced recognize the difference. A fingerprint or signature antigen, and/or epitope within the antigen, may include their posttranslational modifications which may be present in one form and altered or absent in another also such that antibodies recognize the difference.
Variations and immune escape examples have been published by several authors (Caton et al., 1982, The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype, Cell 982:417-27; Ferguson et al., 2003, Ecological and immunological determinants of influenza evolution, Nature 422: 428-433; Drescher et al., 1993, Comparative investigation of the hemagglutinin epitopes of influenza virus A/Brazil/11/78 (H1N1). and its escape variants, J Virol Methods., 42:75-88; Hensley et al., 2009, Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326: 734-736; Table 1), and new variants can be rapidly determined by comparing previous years amino acids sequences, such as within the hemagglutinin, with new sequences, within the well-known and defined epitope regions. The highly neutralizing epitopes of influenza hemagglutinin are designated Sa, Sb, Ca and Cb (Caton et al., 1982, The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype, Cell 982:417-27), where the “S” refers to strain specific antigenic determinants, and the “C” refers to constant antigenic determinants.
5.4. Posttranslational Modifications for Antigens and Epitopes
Viral proteins may include posttranslational modifications whereby structural and/or functional non-peptidal biosynthetic covalent modifications of the polypeptide are formed. Postranslational modifications may include additions of phosphates, acetate, amines, lipids, sialic acid and carbohydrates. Carbohydrate structures, such as Gal alpha 1-3 Gal beta 1-4GlcNAc-R (termed the alpha-gal epitope) on viral glycoproteins is of interest because of the large amounts of natural antibody (anti-Gal) produced in humans against this epitope (Henion et al., 1997, Synthesis of alpha-gal epitopes on influenza virus vaccines, by recombinant alpha 1,3 galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody. Vaccine 15:1174-82). Because not all vaccines may contain glycosylated antigens, glycosylation of an antigen and/or a particular epitope may constitute a signature or fingerprint signature that can be used to distinguish an immune response by comparing the immune response to glycosylated and non-glycosylated counterparts. Likewise, sialic acids may constitute an antigenic portion variable among vaccines (Suzuki, 1993, Variation of influenza viruses and their recognition of the receptor sialo-sugar chains, Yakugaku Zasshi, 113: 556-78) and may be used as a diagnostic signature sequence.
5.5. Antibody-Based Assays.
Antibody assays are well known to those skilled in the arts and include enzyme-linked immunosorbent assays (ELISAs), immunoblots, protein arrays and many others (Ed Harlow and David Lane, Antibodies, A Laboratory Manual. Cold Spring Harbor Press, 1988, 731 pp). Antibody based assays allow the determination of the presence of antibodies (Cheng et al., 2008, Serologic and genetic characterization analysis of a highly pathogenic influenza virus (H5N1) isolated from an infected man in Shenzhen, J. Med. Virol. 80: 1058-1064; Katz et al., 1999, Antibody response in individuals infected with avian influenza A (H5N1) virus and detection of anti-H5 antibody among household and social contacts. J. Infect. Dis. 180: 1763-1770; Rowe et al., 1999, detection of antibody to avian influenza A (H5N1) virus in human serum using a combination of serologic assays, J. Clin. Microbiol. 37: 937-943). Antibody tests test for the presence of antibodies to a particular antigen, or portion of an antigen or specific epitope. Multiple formats exist, and either an antigen, an antibody, or capture antibody or capture ligand may first be adhered to a substrate, exposing it in a manner that allows a secondary exposure which may contain either the antibodies, antigen, or complex thereof, together with the necessary reporter and or detector, respectively, to bind to the antigen (Ed Harlow and David Lane, Antibodies, A Laboratory Manual. Cold Spring Harbor Press, 1988, 731 pp). By specifically detecting the presence of antibodies and their relative amount, knowledge of immunization to a particular parasite or infectious disease such as an influenza virus, either through immunization of one or more vaccines and vaccine antigens, or through natural exposure, can be ascertained. Various bodily fluids may contain antibodies to influenza, including blood (whole, serum or plasma), saliva, urine or (Ed Harlow and David Lane, Antibodies, A Laboratory Manual. Cold Spring Harbor Press, 1988, 731 pp; Urnovitz et al., 1999, Urine Antibody Tests: New Insights into the Dynamics of HIV-1 Infection Clinical Chemistry 45: 1602-1613; Vazquez et al., 2007, Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections, International Journal of Infectious Diseases 11: 256-262), or other mucus membranes such as the nasopharynx, bronchia or lungs.
In testing for antibody responses, tests for IgM are particularly useful for early testing because they constitute an early antibody response to infectious diseases, although IgG generally have a greater data base of well-described epitopes and persist longer. Immunoglobulin capture such as the “IgM capture” assays have been used for infectious disease exposure (Shaikn et al., 2007, Development of a novel, rapid, and sensitive immunochromatographic strip assay specific for west nile virus (WNV) IgM and testing of its diagnostic accuracy in patients suspected of WNV infection, Clin. Chem. 53: 2031-2034; Song, WO/2008/020293, West Nile virus envelope (e) protein antigen and immunoassay). However, these tests do not distinguish among multiple antigens with varying epitopes originating from one or more vaccines, nor among posttranslational modifications of the vaccine antigens.
In order to more fully illustrate the invention, the following examples are provided.
Patients will demonstrate an early antibody response of the IgM type during the first 4 days post vaccine immunization or illness, and nearly all patients will have detectable IgM antibodies by 7 to 8 days thereafter. Influenza-specific serum IgG is detectable by 3 weeks postinfection/inoculation. The virus itself is usually no longer detectable by the time influenza-specific serum IgM appears, although both IgM and IgG may persist for more than a year.
Both the ELISA and the strip format assay can use the same principle and the same antigens. A solid-phase immunochromatographic strip technology to qualitatively detect the presence of antibodies in human serum or plasma has been devised (Shaikh et al., Development of a novel, rapid, and sensitive immunochromatographic strip assay specific for West Nile Virus (WNV) IgM and testing of its diagnostic accuracy in patients suspected of WNV infection, Clin. Chem. 53: 2031-2034) and has been compared with ELISA assays (Tardei et al., 2000, Evaluation of immunoglobin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile virus infection. J Clin Microbiol 38:2232-2239; Martin et al., 2000, Standardization of immunoglobin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 38:1823-1836; Malan et al., 2004, Evaluation of commercial West Nile virus immunoglobulin G (IgG) and IgM enzyme immunoassays show the value of continuous validation. J Clin Microbiol 42:727-733).
The test herein uses one or more specific influenza antigens such as the hemaggutinin, produced in one or more expression systems, such as a bacterium (e.g., Escherichia coli), producing non-glycosylated antigens, or using an insect cell/baculovirus system (Wei et al., 2008, Comparative Efficacy of Neutralizing Antibodies Elicited by Recombinant Hemagglutinin Proteins from Avian H5N1 Influenza Virus, J. Virol., 82: 6200-6208), with or without hexahistidine tag, producing glycosylated antigens (Merten et al., (eds) 2001, Recombinant protein production with prokaryotic and eukaryotic cells; A comparative view on host physiology, Kluwer Academic Publishers; Villaverde and Mattanovich, 2007, Recombinant protein production in the new millennium, Microb. Cell Fact. 6: 33 and references therein). Goat-antihuman IgM is biotinylated (biot-IgM) and a mouse monoclonal IgG anti-antigen antibody is conjugated onto colloidal gold particles (detector component). All 3 reagents are then dispensed onto the polyester pad and lyophilized. Streptavidin is immobilized onto a nitrocellulose (Sartorius) membrane strip at the test-band site. Rabbit antimouse IgG-Fc is immobilized at the control-band site. When the specimen is dispensed into the sample well, it passes through the membrane, which contains antigen, detector, and biot-IgM antibodies. The influenza IgM in the patient sample then forms a tertiary detector/antigen/IgM complex. The formed complex then migrates through the reaction strip and is captured at the test area. Excess, unreacted detector flows through the strip and is captured in the control area. The reactant concentrations are adjusted and optimized by analysis of calibrators, made from pooled influenza-positive sera, so that the test should produce a positive signal at influenza IgM Index value 1.1 of a commercially available IgM Capture ELISA device (Gentaur, Influenza Elisa Kit; comparator device) and negative results below that number.
Examples of positive, negative, and invalid test results are shown in
Antigens used for determining successful immunization are the antigens of a vaccine for which the test is specifically designed to assess. Thus, if a vaccine used a particular hemagglutinin, such as that of Genbank Accession number GQ280797, then the same hemaggutinin can be used to test for vaccination. If more than one vaccine is to be tested for within a single patient, specific areas of the antigen must be selected. The comparison of antigens that are present in different vaccines is based upon knowledge of the current vaccine compositions for which testing is desired. Antigen epitope peptides are selected based upon known antigenic sights, such as Sa, Sb, Ca, and Cb, based on epitope mapping. Prior epitope maps may be used, such as that described by Xu et al., 2010 (Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza, Science 328: 357-360) in order to determine the epitopic region of a new antigen. Hensley et al., 2009 have described escape mutants of an H1N1 influenza. The complete protein sequence of that hemagglutinin (GenBank Accession number AF389118) is compared with the Genbank Accession number GQ280797 for which the hemagglutinin has with a known epitope map (Xu et al., 2010, FIG. 1). The comparison of these two proteins, using the algorithm for DNA Strider (Douglas, 1995, DNA Strider. An inexpensive sequence analysis package for the Macintosh, Mol Biotechnol 3:37-45), is shown in
In order to modify the immunochomatographic strip assay to accommodate IgG, the epitope peptides must be tagged with an epitope tag in order to be recognized by a gold-conjugated detector antibody that is not recognized by an anti-human IgG biotinylated capture antibody. The test herein uses one or more specific fragments of recombinant influenza antigens (signature epitopes, such as those from Table 1, also described in the Example above) that are expressed as a fusion protein with specific antibody tags (e.g., epitope tags such as FLAG (DYKDDDDK) [SEQ ID NO: 003] or myc (EQKLISEEDL) [SEQ ID NO: 004] Jarvik and Telmer, 1998, Epitope tagging, Annual Review of Genetics, 32: 601-618), in one or more expression systems, such as a bacterium (Merten et al., (eds) 2001, Recombinant protein production with prokaryotic and eukaryotic cells; A comparative view on host physiology, Kluwer Academic Publishers; Villaverde and Mattanovich, 2007, Recombinant protein production in the new millennium, Microb. Cell Fact. 6: 33 and references therein). An diagram of a suitable peptide construct and representative peptides for Sa epitopes and a specific corresponding escape mutant of the same epitope is shown in
The test herein uses one or more specific fragments of recombinant influenza antigens (signature epitopes, such as those from Table 1) that are expressed as a fusion protein with specific antibody tags (epitope tags such as FLAG (DYKDDDDK) [SEQ ID NO: 003] or myc (EQKLISEEDL) [SEQ ID NO: 004] Jarvik and Telmer, 1998, Epitope tagging, Annual Review of Genetics, 32: 601-618), in one or more expression systems, such as a bacterium (Escherichia coli; with or without hexahistidine (HHHHHH)-tag) [SEQ ID NO: 005], producing non-glycosylated antigens, or using an insect cell/baculovirus system (Wei et al., 2008, Comparative Efficacy of Neutralizing Antibodies Elicited by Recombinant Hemagglutinin Proteins from Avian H5N1 Influenza Virus, J. Virol., 82: 6200-6208), with or without hexahistidine tag, producing glycosylated antigens (Merten et al., (eds) 2001, Recombinant protein production with prokaryotic and eukaryotic cells; A comparative view on host physiology, Kluwer Academic Publishers; Villaverde and Mattanovich, 2007, Recombinant protein production in the new millennium, Microb. Cell Fact. 6: 33 and references therein), as described above and depicted in
Examples of multivalent positive and negative results are shown in
The various aspects of the disclosure may be combined and subcombined to represent all consistent combinations and subcombinations without departing from the scope of the invention. The invention is limited by neither the specific embodiments of the specification, nor the particular scope of the claims, but rather is to be treated as encompassing the full scope of each aspect disclosed, and the various combinations and permutations, which do not depart from the enabled disclosure herein.
Number | Name | Date | Kind |
---|---|---|---|
3410839 | De et al. | Nov 1968 | A |
3420205 | Morison et al. | Jan 1969 | A |
3620677 | Morison et al. | Nov 1971 | A |
3666421 | Price et al. | May 1972 | A |
3811840 | Bauer et al. | May 1974 | A |
3850752 | Schuurs et al. | Nov 1974 | A |
3876504 | Koffler | Apr 1975 | A |
3915647 | Wright | Oct 1975 | A |
3954564 | Mennen | May 1976 | A |
4022876 | Anbar | May 1977 | A |
4042335 | Clement | Aug 1977 | A |
4059407 | Hochstrasser | Nov 1977 | A |
4067959 | Bolz | Jan 1978 | A |
4071315 | Chateau | Jan 1978 | A |
4090888 | Rademachers et al. | May 1978 | A |
4094647 | Deutsch et al. | Jun 1978 | A |
4122030 | Smith et al. | Oct 1978 | A |
4166105 | Hirschfeld | Aug 1979 | A |
4168146 | Grubb et al. | Sep 1979 | A |
4169138 | Jonsson | Sep 1979 | A |
4184920 | Blixt et al. | Jan 1980 | A |
4208479 | Zuk et al. | Jun 1980 | A |
4230797 | Boguslaski et al. | Oct 1980 | A |
4233402 | Maggio et al. | Nov 1980 | A |
4235601 | Deutsch et al. | Nov 1980 | A |
4244940 | Jeong et al. | Jan 1981 | A |
4246339 | Cole et al. | Jan 1981 | A |
4253844 | Limet et al. | Mar 1981 | A |
4254096 | Monthony et al. | Mar 1981 | A |
4299916 | Litman et al. | Nov 1981 | A |
4301139 | Feingers et al. | Nov 1981 | A |
4302536 | Longenecker | Nov 1981 | A |
4313734 | Leuvering | Feb 1982 | A |
4315907 | Fridlender et al. | Feb 1982 | A |
4315908 | Zer et al. | Feb 1982 | A |
4318707 | Litman et al. | Mar 1982 | A |
4332788 | Mochida et al. | Jun 1982 | A |
4361537 | Deutsch et al. | Nov 1982 | A |
4366241 | Tom et al. | Dec 1982 | A |
4366243 | Rupchock et al. | Dec 1982 | A |
4373932 | Gribnau et al. | Feb 1983 | A |
4374925 | Litman et al. | Feb 1983 | A |
4376110 | David et al. | Mar 1983 | A |
4391904 | Litman et al. | Jul 1983 | A |
4415700 | Batz et al. | Nov 1983 | A |
4435504 | Zuk et al. | Mar 1984 | A |
4442204 | Greenquist et al. | Apr 1984 | A |
4446231 | Self | May 1984 | A |
4446232 | Liotta | May 1984 | A |
4447526 | Rupchock et al. | May 1984 | A |
4452901 | Gordon et al. | Jun 1984 | A |
4461829 | Greenquist | Jul 1984 | A |
4472498 | Masuda et al. | Sep 1984 | A |
4477575 | Vogel et al. | Oct 1984 | A |
4493793 | Chu | Jan 1985 | A |
4514508 | Hirschfeld | Apr 1985 | A |
4518565 | Boger et al. | May 1985 | A |
4552839 | Gould et al. | Nov 1985 | A |
4578399 | Schorlemmer et al. | Mar 1986 | A |
4587102 | Nagatomo et al. | May 1986 | A |
4594327 | Zuk | Jun 1986 | A |
4595655 | Self | Jun 1986 | A |
4595656 | Allen et al. | Jun 1986 | A |
4608246 | Bayer et al. | Aug 1986 | A |
4624804 | Voelter et al. | Nov 1986 | A |
4624929 | Ullman | Nov 1986 | A |
4629690 | Weng et al. | Dec 1986 | A |
4632901 | Valkirs et al. | Dec 1986 | A |
4659678 | Forrest et al. | Apr 1987 | A |
4665018 | Vold | May 1987 | A |
4670381 | Frickey et al. | Jun 1987 | A |
4678757 | Rapkin et al. | Jul 1987 | A |
4695554 | O'Connell et al. | Sep 1987 | A |
4696797 | Kelton | Sep 1987 | A |
4697797 | Gold | Oct 1987 | A |
4703017 | Campbell et al. | Oct 1987 | A |
4707450 | Nason | Nov 1987 | A |
4725406 | Compton et al. | Feb 1988 | A |
4727019 | Valkirs et al. | Feb 1988 | A |
4740468 | Weng et al. | Apr 1988 | A |
4742011 | Blake et al. | May 1988 | A |
4749647 | Thomas et al. | Jun 1988 | A |
4753776 | Hillman et al. | Jun 1988 | A |
4757004 | Houts et al. | Jul 1988 | A |
4770853 | Bernstein | Sep 1988 | A |
4775515 | Cottingham | Oct 1988 | A |
4775636 | Moeremans et al. | Oct 1988 | A |
4777964 | Briggs et al. | Oct 1988 | A |
4780422 | Mitani et al. | Oct 1988 | A |
4786589 | Rounds | Nov 1988 | A |
4786594 | Khanna et al. | Nov 1988 | A |
4786606 | Giegel et al. | Nov 1988 | A |
4788152 | Doeding et al. | Nov 1988 | A |
4790979 | Terminiello et al. | Dec 1988 | A |
4791056 | Sizto et al. | Dec 1988 | A |
4803170 | Stanton et al. | Feb 1989 | A |
4806311 | Greenquist | Feb 1989 | A |
4806312 | Greenquist | Feb 1989 | A |
4810470 | Burkhardt et al. | Mar 1989 | A |
4816224 | Vogel et al. | Mar 1989 | A |
4816392 | Hokama | Mar 1989 | A |
4818677 | Hay-Kaufman et al. | Apr 1989 | A |
4824784 | Cantarow | Apr 1989 | A |
4837145 | Liotta | Jun 1989 | A |
4837168 | de Jaeger et al. | Jun 1989 | A |
4843000 | Litman et al. | Jun 1989 | A |
4849338 | Litman et al. | Jul 1989 | A |
4853335 | Olsen et al. | Aug 1989 | A |
4855240 | Rosenstein et al. | Aug 1989 | A |
4857453 | Ullman et al. | Aug 1989 | A |
4859612 | Cole et al. | Aug 1989 | A |
4861552 | Masuda et al. | Aug 1989 | A |
4861711 | Friesen et al. | Aug 1989 | A |
4868106 | Ito et al. | Sep 1989 | A |
4868108 | Bahar et al. | Sep 1989 | A |
4870005 | Akiyoshi et al. | Sep 1989 | A |
4874691 | Chandler | Oct 1989 | A |
4879215 | Weng et al. | Nov 1989 | A |
4900663 | Wie et al. | Feb 1990 | A |
4906439 | Grenner | Mar 1990 | A |
4910150 | Doeding et al. | Mar 1990 | A |
4914040 | Lenz et al. | Apr 1990 | A |
4916056 | Brown, III et al. | Apr 1990 | A |
4920046 | McFarland et al. | Apr 1990 | A |
4929544 | Vold | May 1990 | A |
4931385 | Block et al. | Jun 1990 | A |
4933092 | Aunet et al. | Jun 1990 | A |
4940456 | Sibalis et al. | Jul 1990 | A |
4943522 | Eisinger et al. | Jul 1990 | A |
4943552 | Osajima et al. | Jul 1990 | A |
4945045 | Forrest et al. | Jul 1990 | A |
4954452 | Yost et al. | Sep 1990 | A |
4956275 | Zuk et al. | Sep 1990 | A |
4956302 | Gordon et al. | Sep 1990 | A |
4956303 | Self | Sep 1990 | A |
4959305 | Woodrum | Sep 1990 | A |
4959307 | Olson | Sep 1990 | A |
4960691 | Gordon et al. | Oct 1990 | A |
4978610 | Forrest et al. | Dec 1990 | A |
4981786 | Dafforn et al. | Jan 1991 | A |
4987085 | Allen et al. | Jan 1991 | A |
4990442 | Del Campo | Feb 1991 | A |
4994373 | Stavrianopoulos et al. | Feb 1991 | A |
5008080 | Brown, III et al. | Apr 1991 | A |
5019496 | Oster et al. | May 1991 | A |
5026653 | Lee et al. | Jun 1991 | A |
5028535 | Buechler et al. | Jul 1991 | A |
5030558 | Litman et al. | Jul 1991 | A |
5035997 | Oster et al. | Jul 1991 | A |
5059522 | Wayne | Oct 1991 | A |
5073340 | Covington et al. | Dec 1991 | A |
5073484 | Swanson et al. | Dec 1991 | A |
5079142 | Coleman et al. | Jan 1992 | A |
5085987 | Olson | Feb 1992 | A |
5085988 | Olson | Feb 1992 | A |
5089391 | Buechler et al. | Feb 1992 | A |
5089394 | Chun et al. | Feb 1992 | A |
5091318 | Anawis et al. | Feb 1992 | A |
5096833 | Lau et al. | Mar 1992 | A |
5102788 | Cole | Apr 1992 | A |
5103836 | Goldstein et al. | Apr 1992 | A |
5104793 | Buck | Apr 1992 | A |
5120504 | Petro-Roy et al. | Jun 1992 | A |
5120643 | Ching et al. | Jun 1992 | A |
5135719 | Hillman et al. | Aug 1992 | A |
5137804 | Greene et al. | Aug 1992 | A |
5137808 | Ullman et al. | Aug 1992 | A |
5139685 | de Castro et al. | Aug 1992 | A |
5141850 | Cole et al. | Aug 1992 | A |
5141875 | Kelton et al. | Aug 1992 | A |
5142031 | Lee et al. | Aug 1992 | A |
5143852 | Valkirs et al. | Sep 1992 | A |
5145789 | Corti et al. | Sep 1992 | A |
5149622 | Brown et al. | Sep 1992 | A |
5149630 | Forrest et al. | Sep 1992 | A |
5156952 | Litman et al. | Oct 1992 | A |
5156953 | Litman et al. | Oct 1992 | A |
5158869 | Pouletty et al. | Oct 1992 | A |
5160701 | Brown, III et al. | Nov 1992 | A |
5166051 | Killeen et al. | Nov 1992 | A |
5171688 | Hewett et al. | Dec 1992 | A |
5177021 | Kondo | Jan 1993 | A |
5183740 | Ligler et al. | Feb 1993 | A |
5185245 | Heimer | Feb 1993 | A |
5188938 | Khanna et al. | Feb 1993 | A |
5196302 | Kidwell | Mar 1993 | A |
5196306 | Bobrow et al. | Mar 1993 | A |
5200312 | Oprandy | Apr 1993 | A |
5200321 | Kidwell | Apr 1993 | A |
5202233 | Herrmann et al. | Apr 1993 | A |
5206136 | Monji et al. | Apr 1993 | A |
5206177 | DeLaCroix et al. | Apr 1993 | A |
5212065 | Pegg et al. | May 1993 | A |
5225330 | Ginsburg et al. | Jul 1993 | A |
5232830 | Van Ness | Aug 1993 | A |
5232835 | Litman et al. | Aug 1993 | A |
RE34405 | Gould et al. | Oct 1993 | E |
5250412 | Giegel | Oct 1993 | A |
5258163 | Krause et al. | Nov 1993 | A |
5260193 | Olson | Nov 1993 | A |
5260221 | Ramel et al. | Nov 1993 | A |
5260428 | Herrmann et al. | Nov 1993 | A |
5262067 | Wilk et al. | Nov 1993 | A |
5292636 | Kung et al. | Mar 1994 | A |
5308775 | Donovan et al. | May 1994 | A |
5335673 | Goldstein et al. | Aug 1994 | A |
5340539 | Allen et al. | Aug 1994 | A |
5342759 | Litman et al. | Aug 1994 | A |
5352582 | Lichtenwalter et al. | Oct 1994 | A |
5354692 | Yang et al. | Oct 1994 | A |
5356782 | Moorman et al. | Oct 1994 | A |
5364533 | Ogura et al. | Nov 1994 | A |
5369007 | Kidwell | Nov 1994 | A |
5374524 | Miller | Dec 1994 | A |
5376337 | Seymour | Dec 1994 | A |
5384264 | Chen et al. | Jan 1995 | A |
5391272 | O'Daly et al. | Feb 1995 | A |
5391478 | Greene et al. | Feb 1995 | A |
5401634 | Milbrath | Mar 1995 | A |
5418171 | Kimura et al. | May 1995 | A |
5423989 | Allen et al. | Jun 1995 | A |
5424193 | Pronovost et al. | Jun 1995 | A |
5435970 | Mamenta et al. | Jul 1995 | A |
5437983 | Watts et al. | Aug 1995 | A |
5443953 | Hansen et al. | Aug 1995 | A |
5460978 | Martin et al. | Oct 1995 | A |
5468622 | Richards | Nov 1995 | A |
5468648 | Chandler | Nov 1995 | A |
5474911 | Pontius | Dec 1995 | A |
5478729 | Van Atta et al. | Dec 1995 | A |
5480792 | Buechler et al. | Jan 1996 | A |
5494646 | Seymour | Feb 1996 | A |
5501949 | Marshall | Mar 1996 | A |
5507410 | Clark et al. | Apr 1996 | A |
5521102 | Boehringer et al. | May 1996 | A |
5521289 | Hainfeld et al. | May 1996 | A |
5527686 | Fitzpatrick et al. | Jun 1996 | A |
5529904 | Ginsburg et al. | Jun 1996 | A |
5536471 | Clark et al. | Jul 1996 | A |
5540890 | Clark et al. | Jul 1996 | A |
5541115 | Siegel et al. | Jul 1996 | A |
5550032 | Isbister | Aug 1996 | A |
5556756 | Olsen et al. | Sep 1996 | A |
5558834 | Chu et al. | Sep 1996 | A |
5559041 | Kang et al. | Sep 1996 | A |
5573919 | Kearns et al. | Nov 1996 | A |
5575978 | Clark et al. | Nov 1996 | A |
5578459 | Gordon et al. | Nov 1996 | A |
5578494 | Clark et al. | Nov 1996 | A |
5580561 | Cercek et al. | Dec 1996 | A |
5580790 | Wall et al. | Dec 1996 | A |
5583001 | Bobrow et al. | Dec 1996 | A |
5591645 | Rosenstein | Jan 1997 | A |
5602040 | May et al. | Feb 1997 | A |
5605665 | Clark et al. | Feb 1997 | A |
5607863 | Chandler | Mar 1997 | A |
5610069 | Clark et al. | Mar 1997 | A |
5620845 | Gould et al. | Apr 1997 | A |
5620859 | Garry et al. | Apr 1997 | A |
5622871 | May et al. | Apr 1997 | A |
5627522 | Walker et al. | May 1997 | A |
5635362 | Levine et al. | Jun 1997 | A |
5635364 | Clark et al. | Jun 1997 | A |
5635603 | Hansen et al. | Jun 1997 | A |
5637468 | Mason | Jun 1997 | A |
5646049 | Tayi | Jul 1997 | A |
5650333 | Holtlund et al. | Jul 1997 | A |
5654162 | Guire et al. | Aug 1997 | A |
5654401 | Clements et al. | Aug 1997 | A |
5656502 | MacKay et al. | Aug 1997 | A |
5656503 | May et al. | Aug 1997 | A |
5663303 | Rochette-Egly et al. | Sep 1997 | A |
5665534 | Vandenbergh et al. | Sep 1997 | A |
5667976 | Van Ness et al. | Sep 1997 | A |
5679526 | Buechler et al. | Oct 1997 | A |
5686315 | Pronovost et al. | Nov 1997 | A |
5691207 | Holtlund et al. | Nov 1997 | A |
5703207 | Martin et al. | Dec 1997 | A |
5707820 | Wilsey et al. | Jan 1998 | A |
5712170 | Kouvonen et al. | Jan 1998 | A |
5712172 | Huang et al. | Jan 1998 | A |
5714389 | Charlton et al. | Feb 1998 | A |
5716778 | Weng et al. | Feb 1998 | A |
5723345 | Yamauchi et al. | Mar 1998 | A |
5725774 | Neyer | Mar 1998 | A |
5726010 | Clark | Mar 1998 | A |
5726013 | Clark | Mar 1998 | A |
5728587 | Kang et al. | Mar 1998 | A |
5728590 | Powell | Mar 1998 | A |
5731158 | Bobrow et al. | Mar 1998 | A |
5739041 | Nazareth et al. | Apr 1998 | A |
5741652 | Shibuya et al. | Apr 1998 | A |
5747254 | Pontius | May 1998 | A |
5750333 | Clark | May 1998 | A |
5759794 | Levine et al. | Jun 1998 | A |
5762878 | Clark et al. | Jun 1998 | A |
5763262 | Wong et al. | Jun 1998 | A |
5766886 | Studnicka et al. | Jun 1998 | A |
5766961 | Pawlak et al. | Jun 1998 | A |
5770196 | Studnicka | Jun 1998 | A |
5770395 | Isbister | Jun 1998 | A |
5770460 | Pawlak et al. | Jun 1998 | A |
5776710 | Levine et al. | Jul 1998 | A |
5789154 | Durst et al. | Aug 1998 | A |
5798215 | Cathey et al. | Aug 1998 | A |
5811525 | Rittershaus | Sep 1998 | A |
5817473 | Das et al. | Oct 1998 | A |
5820826 | Moorman | Oct 1998 | A |
5821073 | Lee | Oct 1998 | A |
5821123 | Studnicka | Oct 1998 | A |
5833923 | McClintock et al. | Nov 1998 | A |
5833924 | McClintock et al. | Nov 1998 | A |
5834215 | Garry et al. | Nov 1998 | A |
5834217 | Levine et al. | Nov 1998 | A |
5843680 | Manian et al. | Dec 1998 | A |
5843794 | Singer | Dec 1998 | A |
5846838 | Chandler | Dec 1998 | A |
5866322 | Jou et al. | Feb 1999 | A |
5866363 | Pieczenik | Feb 1999 | A |
5869345 | Chandler | Feb 1999 | A |
5869619 | Studnicka | Feb 1999 | A |
5872221 | Martin et al. | Feb 1999 | A |
5877028 | Chandler et al. | Mar 1999 | A |
5879881 | Rubenstein | Mar 1999 | A |
5879951 | Sy | Mar 1999 | A |
5900379 | Noda et al. | May 1999 | A |
5916521 | Bunce et al. | Jun 1999 | A |
5929049 | Singh et al. | Jul 1999 | A |
5932174 | Brayton et al. | Aug 1999 | A |
5939252 | Lennon et al. | Aug 1999 | A |
5939272 | Buechler et al. | Aug 1999 | A |
5939331 | Burd et al. | Aug 1999 | A |
5942407 | Liotta et al. | Aug 1999 | A |
5962336 | Sun | Oct 1999 | A |
5965458 | Kouvonen et al. | Oct 1999 | A |
5976824 | Gordon | Nov 1999 | A |
5985579 | Buechler et al. | Nov 1999 | A |
5989921 | Charlton et al. | Nov 1999 | A |
5998220 | Chandler | Dec 1999 | A |
5998221 | Malick et al. | Dec 1999 | A |
6001658 | Fredrickson | Dec 1999 | A |
6007999 | Clark | Dec 1999 | A |
6008056 | Thieme | Dec 1999 | A |
6008059 | Schrier et al. | Dec 1999 | A |
6017698 | Bienhaus et al. | Jan 2000 | A |
6017767 | Chandler | Jan 2000 | A |
6025477 | Calenoff | Feb 2000 | A |
6027904 | Devine et al. | Feb 2000 | A |
6030773 | Agnello | Feb 2000 | A |
6046057 | Nazareth et al. | Apr 2000 | A |
6046058 | Sun | Apr 2000 | A |
6060237 | Nygren et al. | May 2000 | A |
6084092 | Wakshull et al. | Jul 2000 | A |
6086748 | Durst et al. | Jul 2000 | A |
6096561 | Tayi | Aug 2000 | A |
6100099 | Gordon et al. | Aug 2000 | A |
6121425 | Hainfeld et al. | Sep 2000 | A |
6132682 | Christner et al. | Oct 2000 | A |
6133227 | Barnabas et al. | Oct 2000 | A |
6136549 | Feistel | Oct 2000 | A |
6140136 | Lee | Oct 2000 | A |
6146589 | Chandler | Nov 2000 | A |
6153147 | Craig | Nov 2000 | A |
6156271 | May | Dec 2000 | A |
6156742 | Mackenzie | Dec 2000 | A |
6165796 | Bell | Dec 2000 | A |
6168956 | Chandler | Jan 2001 | B1 |
6171801 | Staples et al. | Jan 2001 | B1 |
6187598 | May et al. | Feb 2001 | B1 |
6190617 | Clark et al. | Feb 2001 | B1 |
6194222 | Buechler et al. | Feb 2001 | B1 |
6194225 | Oka et al. | Feb 2001 | B1 |
6197598 | Schrier et al. | Mar 2001 | B1 |
6210898 | Bouma et al. | Apr 2001 | B1 |
6225074 | Wright et al. | May 2001 | B1 |
6228602 | Pugia | May 2001 | B1 |
6228660 | May et al. | May 2001 | B1 |
6245296 | Ligler et al. | Jun 2001 | B1 |
6245577 | McVicker et al. | Jun 2001 | B1 |
6248596 | Durst et al. | Jun 2001 | B1 |
6262264 | Buck, Jr. et al. | Jul 2001 | B1 |
6271044 | Ballerstadt et al. | Aug 2001 | B1 |
6277647 | Christner et al. | Aug 2001 | B1 |
6277650 | Nazareth et al. | Aug 2001 | B1 |
6284194 | Chu | Sep 2001 | B1 |
6294062 | Buck, Jr. et al. | Sep 2001 | B1 |
6294321 | Wakshull et al. | Sep 2001 | B1 |
6297020 | Brock | Oct 2001 | B1 |
6306614 | Romaschin et al. | Oct 2001 | B1 |
6319676 | Nazareth et al. | Nov 2001 | B1 |
6325980 | Christner et al. | Dec 2001 | B1 |
6326139 | Soreq et al. | Dec 2001 | B1 |
6335205 | Bausback | Jan 2002 | B1 |
6352824 | Buck, Jr. et al. | Mar 2002 | B1 |
6352862 | Davis et al. | Mar 2002 | B1 |
6355429 | Nygren et al. | Mar 2002 | B1 |
6358752 | Durst et al. | Mar 2002 | B1 |
6365417 | Fleming et al. | Apr 2002 | B1 |
6368876 | Huang et al. | Apr 2002 | B1 |
6369206 | Leone et al. | Apr 2002 | B1 |
6372514 | Lee | Apr 2002 | B1 |
6387622 | Siiman et al. | May 2002 | B1 |
6403298 | Lee et al. | Jun 2002 | B1 |
6403384 | Lea | Jun 2002 | B1 |
6413473 | Bacon | Jul 2002 | B1 |
6413715 | Wakshull et al. | Jul 2002 | B2 |
6416962 | Das et al. | Jul 2002 | B1 |
6416975 | Gallagher et al. | Jul 2002 | B1 |
6436649 | Kohl et al. | Aug 2002 | B1 |
6485982 | Charlton | Nov 2002 | B1 |
6489309 | Singh et al. | Dec 2002 | B1 |
6509196 | Brooks et al. | Jan 2003 | B1 |
6514769 | Lee | Feb 2003 | B2 |
6528325 | Hubscher et al. | Mar 2003 | B1 |
6534008 | Angros | Mar 2003 | B1 |
6534320 | Ching et al. | Mar 2003 | B2 |
6537828 | Nakaya et al. | Mar 2003 | B1 |
6541277 | Kang et al. | Apr 2003 | B1 |
6551834 | Carpenter et al. | Apr 2003 | B2 |
6558959 | Chu | May 2003 | B2 |
6576460 | Baeumner et al. | Jun 2003 | B1 |
6605448 | Pieczenik | Aug 2003 | B1 |
6627459 | Tung et al. | Sep 2003 | B1 |
6635469 | Litt et al. | Oct 2003 | B1 |
6649830 | Bartlett et al. | Nov 2003 | B1 |
6656744 | Pronovost et al. | Dec 2003 | B2 |
6660534 | McVicker et al. | Dec 2003 | B2 |
6689317 | Rees | Feb 2004 | B1 |
6699722 | Bauer et al. | Mar 2004 | B2 |
6713271 | Feistel | Mar 2004 | B1 |
6723840 | Sakowicz et al. | Apr 2004 | B1 |
6730268 | Lee et al. | May 2004 | B2 |
6733983 | Houthoff et al. | May 2004 | B1 |
6764830 | Sakowicz et al. | Jul 2004 | B1 |
6767710 | DiNello et al. | Jul 2004 | B2 |
6767714 | Nazareth et al. | Jul 2004 | B2 |
6808889 | Fitzpatrick et al. | Oct 2004 | B2 |
6815169 | Sakowicz et al. | Nov 2004 | B1 |
6818455 | May et al. | Nov 2004 | B2 |
6824975 | Hubscher et al. | Nov 2004 | B2 |
6828110 | Lee et al. | Dec 2004 | B2 |
6841159 | Simonson | Jan 2005 | B2 |
6855292 | Angros | Feb 2005 | B2 |
6855561 | Jerome et al. | Feb 2005 | B2 |
6887669 | Staples et al. | May 2005 | B1 |
6905816 | Jacobs et al. | Jun 2005 | B2 |
6924153 | Boehringer | Aug 2005 | B1 |
6949524 | Singh et al. | Sep 2005 | B2 |
6991912 | Feistel | Jan 2006 | B2 |
7026449 | Baker et al. | Apr 2006 | B2 |
7045310 | Buck, Jr. et al. | May 2006 | B2 |
7045342 | Nazareth et al. | May 2006 | B2 |
7052831 | Fletcher et al. | May 2006 | B2 |
7064197 | Rabbani et al. | Jun 2006 | B1 |
7144742 | Boehringer et al. | Dec 2006 | B2 |
7145019 | Olejnik et al. | Dec 2006 | B2 |
7169906 | Ferrara et al. | Jan 2007 | B2 |
7172874 | Hollyfield et al. | Feb 2007 | B2 |
7175992 | Fong | Feb 2007 | B2 |
7179657 | Jerome et al. | Feb 2007 | B2 |
7189522 | Esfandiari | Mar 2007 | B2 |
RE39664 | Gordon et al. | May 2007 | E |
7223535 | Fields et al. | May 2007 | B2 |
7226793 | Jerome et al. | Jun 2007 | B2 |
7238322 | Wang et al. | Jul 2007 | B2 |
7244252 | Berndt | Jul 2007 | B2 |
7247500 | Wei et al. | Jul 2007 | B2 |
7250301 | Angros | Jul 2007 | B2 |
7252950 | Vale et al. | Aug 2007 | B1 |
7270959 | Hudak | Sep 2007 | B2 |
7300627 | Sun | Nov 2007 | B1 |
7300633 | Hudak et al. | Nov 2007 | B2 |
7315378 | Phelan et al. | Jan 2008 | B2 |
7317092 | Ashkenazi et al. | Jan 2008 | B2 |
7317532 | Sharrock et al. | Jan 2008 | B2 |
7321065 | Scanlan et al. | Jan 2008 | B2 |
7341839 | Hollyfield et al. | Mar 2008 | B2 |
7347972 | Lee | Mar 2008 | B1 |
RE40198 | Buck, Jr. et al. | Apr 2008 | E |
7355079 | Scanlan et al. | Apr 2008 | B2 |
7358055 | Valkirs et al. | Apr 2008 | B2 |
7361473 | Valkirs et al. | Apr 2008 | B2 |
7371584 | Feistel | May 2008 | B2 |
7390626 | Vojdani | Jun 2008 | B2 |
7390674 | Feaster et al. | Jun 2008 | B2 |
7390675 | Feistel | Jun 2008 | B2 |
7393647 | Valkirs et al. | Jul 2008 | B2 |
7393656 | Perez et al. | Jul 2008 | B2 |
7396689 | Dowd et al. | Jul 2008 | B2 |
7410763 | Su et al. | Aug 2008 | B2 |
7419796 | Durst et al. | Sep 2008 | B2 |
7476362 | Angros | Jan 2009 | B2 |
7476502 | Willey | Jan 2009 | B2 |
7491551 | Boehringer et al. | Feb 2009 | B2 |
7498302 | Ng et al. | Mar 2009 | B2 |
7507420 | Ng et al. | Mar 2009 | B2 |
7517495 | Wu et al. | Apr 2009 | B2 |
7517699 | Bauer et al. | Apr 2009 | B2 |
7517903 | Chen et al. | Apr 2009 | B2 |
7537937 | Jerome et al. | May 2009 | B2 |
7553675 | Jerome et al. | Jun 2009 | B2 |
7560257 | Hollyfield et al. | Jul 2009 | B2 |
7560272 | Ramsey et al. | Jul 2009 | B2 |
7560431 | Zankel et al. | Jul 2009 | B2 |
7563584 | Perez et al. | Jul 2009 | B2 |
7566533 | Jacobs et al. | Jul 2009 | B2 |
7569544 | Zankel et al. | Aug 2009 | B2 |
7572640 | Goix et al. | Aug 2009 | B2 |
7595160 | White et al. | Sep 2009 | B2 |
7595198 | Olejnik et al. | Sep 2009 | B2 |
7622077 | Angros | Nov 2009 | B2 |
7622250 | Jacobs et al. | Nov 2009 | B2 |
7632461 | Angros | Dec 2009 | B2 |
7632687 | Gokhan | Dec 2009 | B2 |
7655184 | Wang et al. | Feb 2010 | B2 |
7662643 | Wei et al. | Feb 2010 | B2 |
7678760 | Tang et al. | Mar 2010 | B2 |
7682801 | Esfandiari | Mar 2010 | B2 |
7691595 | Fong | Apr 2010 | B2 |
7691962 | Boyd et al. | Apr 2010 | B2 |
7695929 | Kosmeder et al. | Apr 2010 | B2 |
7700554 | Beliveau et al. | Apr 2010 | B2 |
7709215 | Scuderi | May 2010 | B2 |
7713703 | Buechler et al. | May 2010 | B1 |
7713709 | White et al. | May 2010 | B2 |
7714016 | Gangwar et al. | May 2010 | B2 |
7718388 | Baeumner | May 2010 | B2 |
7736660 | Elsemore et al. | Jun 2010 | B2 |
7741046 | Larsen et al. | Jun 2010 | B2 |
7754211 | Rosenblum et al. | Jul 2010 | B2 |
7763454 | Nazareth et al. | Jul 2010 | B2 |
7781170 | Tonelli et al. | Aug 2010 | B2 |
7781209 | Mancebo et al. | Aug 2010 | B2 |
7781226 | McDevitt et al. | Aug 2010 | B2 |
7785899 | Saul et al. | Aug 2010 | B2 |
7794656 | Liang et al. | Sep 2010 | B2 |
7795038 | Jones et al. | Sep 2010 | B2 |
7822245 | Wang | Oct 2010 | B2 |
7824879 | Khan et al. | Nov 2010 | B2 |
7829537 | Zankel et al. | Nov 2010 | B2 |
7829669 | Koelsch et al. | Nov 2010 | B2 |
7842823 | Chang | Nov 2010 | B2 |
7847105 | Gangwar et al. | Dec 2010 | B2 |
7855054 | Schneider et al. | Dec 2010 | B2 |
7858397 | Durst et al. | Dec 2010 | B2 |
D631556 | Shi et al. | Jan 2011 | S |
7867780 | Jones et al. | Jan 2011 | B2 |
7871568 | Liang et al. | Jan 2011 | B2 |
7871781 | Rundstrom et al. | Jan 2011 | B2 |
7875433 | Harris | Jan 2011 | B2 |
7879293 | Niedbala et al. | Feb 2011 | B2 |
7879597 | Esfandiari | Feb 2011 | B2 |
7885444 | Wang | Feb 2011 | B2 |
7888049 | Shaari | Feb 2011 | B2 |
7888470 | Li et al. | Feb 2011 | B2 |
7897330 | Patel et al. | Mar 2011 | B2 |
7914734 | Livingston | Mar 2011 | B2 |
7914999 | Grenier et al. | Mar 2011 | B2 |
7927791 | Welch et al. | Apr 2011 | B2 |
7939278 | Perez et al. | May 2011 | B2 |
7943334 | Akimoto et al. | May 2011 | B2 |
7951547 | Elsemore et al. | May 2011 | B2 |
7964415 | Zhelev et al. | Jun 2011 | B2 |
7968586 | Gangwar et al. | Jun 2011 | B2 |
7977317 | Beliveau et al. | Jul 2011 | B2 |
7977465 | Ng et al. | Jul 2011 | B2 |
7993851 | Holets-McCormack | Aug 2011 | B2 |
7993861 | Elsemore et al. | Aug 2011 | B2 |
7993862 | Elsemore et al. | Aug 2011 | B2 |
7995194 | Wardlaw et al. | Aug 2011 | B2 |
7998679 | Jacobs et al. | Aug 2011 | B2 |
8003407 | Zhou et al. | Aug 2011 | B2 |
8007720 | Angros | Aug 2011 | B2 |
8007721 | Angros | Aug 2011 | B2 |
8021895 | Kienle et al. | Sep 2011 | B2 |
8025850 | Chan | Sep 2011 | B2 |
8030091 | Jerome et al. | Oct 2011 | B2 |
8034576 | Bricker et al. | Oct 2011 | B2 |
8034959 | Ng et al. | Oct 2011 | B2 |
8052927 | Angros | Nov 2011 | B2 |
8062841 | Su et al. | Nov 2011 | B2 |
8062842 | Vanmechelen et al. | Nov 2011 | B2 |
8067188 | Toranto et al. | Nov 2011 | B2 |
8067241 | Gerdes et al. | Nov 2011 | B2 |
8067246 | Marlborough et al. | Nov 2011 | B2 |
8071023 | Angros | Dec 2011 | B2 |
8071323 | Dimitrov et al. | Dec 2011 | B2 |
8071388 | Huang et al. | Dec 2011 | B2 |
8084272 | Campbell et al. | Dec 2011 | B2 |
8092742 | Angros | Jan 2012 | B2 |
8097261 | Elsemore et al. | Jan 2012 | B2 |
8105794 | Shaari | Jan 2012 | B2 |
8105795 | Elsemore et al. | Jan 2012 | B2 |
8114633 | Weber et al. | Feb 2012 | B2 |
8148094 | Nolan et al. | Apr 2012 | B2 |
8178346 | Mancebo et al. | May 2012 | B2 |
8202734 | Jerome et al. | Jun 2012 | B2 |
8206939 | Perez et al. | Jun 2012 | B2 |
8221700 | Steinmiller et al. | Jul 2012 | B2 |
8264684 | Livingston | Sep 2012 | B2 |
8268574 | Elsemore et al. | Sep 2012 | B2 |
8268639 | Yamashita et al. | Sep 2012 | B2 |
8269163 | Pevsner | Sep 2012 | B2 |
8278421 | Masat et al. | Oct 2012 | B2 |
8283127 | Pfleger et al. | Oct 2012 | B2 |
8287817 | Chan | Oct 2012 | B2 |
8288544 | Diebold et al. | Oct 2012 | B2 |
8293904 | Diebold et al. | Oct 2012 | B2 |
8304195 | Hagen et al. | Nov 2012 | B2 |
8309316 | Perez et al. | Nov 2012 | B2 |
8309318 | Dorval et al. | Nov 2012 | B2 |
8313694 | Angros | Nov 2012 | B2 |
8319954 | Wardlaw et al. | Nov 2012 | B2 |
8323903 | Archer et al. | Dec 2012 | B2 |
8323914 | Toranto et al. | Dec 2012 | B2 |
8329100 | Angros | Dec 2012 | B2 |
8329415 | Holets-McCormack | Dec 2012 | B2 |
8329647 | Pfuetzner et al. | Dec 2012 | B2 |
8338572 | Scuderi et al. | Dec 2012 | B2 |
8354058 | Angros | Jan 2013 | B2 |
8361734 | Bricker et al. | Jan 2013 | B2 |
8367808 | Elsemore et al. | Feb 2013 | B2 |
8377864 | Catelas et al. | Feb 2013 | B2 |
8394599 | Perez et al. | Mar 2013 | B2 |
8394626 | Ramsey et al. | Mar 2013 | B2 |
8399403 | Boyd et al. | Mar 2013 | B2 |
8404455 | Li et al. | Mar 2013 | B2 |
8415163 | Yamashita et al. | Apr 2013 | B2 |
8440629 | Starr et al. | May 2013 | B2 |
8445218 | Pieribone | May 2013 | B2 |
8450072 | Dodds | May 2013 | B2 |
8450074 | Dodds | May 2013 | B2 |
8455202 | Regnier et al. | Jun 2013 | B2 |
8455203 | Wang et al. | Jun 2013 | B2 |
8455263 | Lee | Jun 2013 | B2 |
8461117 | Sufi et al. | Jun 2013 | B2 |
8462339 | Livingston | Jun 2013 | B2 |
8476079 | Campbell et al. | Jul 2013 | B2 |
8480975 | Steinmiller et al. | Jul 2013 | B2 |
8481690 | Murthy et al. | Jul 2013 | B2 |
8486717 | O'Farrell et al. | Jul 2013 | B2 |
8507215 | Salant et al. | Aug 2013 | B2 |
8507218 | Heller et al. | Aug 2013 | B2 |
8507259 | Esfandiari | Aug 2013 | B2 |
8535894 | Archer et al. | Sep 2013 | B2 |
8541187 | Passavant et al. | Sep 2013 | B2 |
8557534 | Turecek et al. | Oct 2013 | B2 |
8557604 | Song | Oct 2013 | B2 |
8557989 | Diebold et al. | Oct 2013 | B2 |
8568719 | Williamson et al. | Oct 2013 | B2 |
8568997 | Pfleger et al. | Oct 2013 | B2 |
8569462 | Bedinger et al. | Oct 2013 | B2 |
8574494 | Angros | Nov 2013 | B2 |
8580518 | Elsemore et al. | Nov 2013 | B2 |
8586375 | Chan | Nov 2013 | B2 |
8603835 | Esfandiari | Dec 2013 | B2 |
8609103 | Zankel et al. | Dec 2013 | B2 |
8617826 | Collier et al. | Dec 2013 | B2 |
8623635 | Nazareth et al. | Jan 2014 | B2 |
8634075 | Livingston | Jan 2014 | B2 |
8642330 | Rock et al. | Feb 2014 | B2 |
8658434 | Mao et al. | Feb 2014 | B2 |
8664407 | Chen et al. | Mar 2014 | B2 |
8673239 | Niedbala et al. | Mar 2014 | B2 |
8685711 | Goix et al. | Apr 2014 | B2 |
8696988 | Angros | Apr 2014 | B2 |
8697365 | Grenier et al. | Apr 2014 | B2 |
8703504 | Song | Apr 2014 | B2 |
8709792 | Saul et al. | Apr 2014 | B2 |
8722019 | Jefferies et al. | May 2014 | B2 |
8722395 | Nazareth et al. | May 2014 | B2 |
8735081 | Li et al. | May 2014 | B2 |
8735367 | Heemstra | May 2014 | B2 |
8735546 | Ghayur et al. | May 2014 | B2 |
8741580 | Kienle et al. | Jun 2014 | B2 |
8765437 | Koppaka et al. | Jul 2014 | B2 |
8791258 | Chang | Jul 2014 | B2 |
8795627 | Starr et al. | Aug 2014 | B2 |
8802029 | Steinmiller et al. | Aug 2014 | B2 |
8815527 | Perez et al. | Aug 2014 | B2 |
8828329 | Sturman et al. | Sep 2014 | B2 |
8828665 | Valdez et al. | Sep 2014 | B2 |
8828676 | Weber et al. | Sep 2014 | B2 |
8828738 | Campbell et al. | Sep 2014 | B2 |
8835835 | Pevsner | Sep 2014 | B2 |
8841079 | Scuderi et al. | Sep 2014 | B2 |
8842264 | Wardlaw et al. | Sep 2014 | B2 |
8846320 | Kosmeder et al. | Sep 2014 | B2 |
8865420 | Perez et al. | Oct 2014 | B2 |
8865458 | Ramsey et al. | Oct 2014 | B2 |
8865875 | Liu et al. | Oct 2014 | B2 |
8877450 | Esfandiari | Nov 2014 | B2 |
8883417 | Jacobs et al. | Nov 2014 | B2 |
8883489 | Pang et al. | Nov 2014 | B2 |
8895050 | Tachdjian et al. | Nov 2014 | B2 |
8895294 | Elsemore et al. | Nov 2014 | B2 |
8900881 | Lee | Dec 2014 | B2 |
8916389 | Iwasaki et al. | Dec 2014 | B2 |
8917392 | Livingston | Dec 2014 | B2 |
8940513 | Koppaka et al. | Jan 2015 | B2 |
8940866 | Heller et al. | Jan 2015 | B2 |
8951736 | Schmidt | Feb 2015 | B2 |
8951749 | Rylatt et al. | Feb 2015 | B2 |
8956859 | Bermudes | Feb 2015 | B1 |
8962263 | Perez et al. | Feb 2015 | B2 |
8968678 | Hu | Mar 2015 | B2 |
8980572 | Wong et al. | Mar 2015 | B2 |
9012393 | Catelas et al. | Apr 2015 | B2 |
9018017 | Campbell et al. | Apr 2015 | B2 |
9034657 | Rundstrom et al. | May 2015 | B2 |
9040245 | Elsemore et al. | May 2015 | B2 |
9046513 | Ghayur et al. | Jun 2015 | B2 |
9063129 | Elsemore et al. | Jun 2015 | B2 |
9063131 | Goix et al. | Jun 2015 | B2 |
9063157 | Katagiri et al. | Jun 2015 | B2 |
9068994 | Collier et al. | Jun 2015 | B2 |
9072313 | Shigemura et al. | Jul 2015 | B2 |
9091684 | Yerramilli et al. | Jul 2015 | B2 |
9091686 | Li et al. | Jul 2015 | B2 |
9102754 | Napper et al. | Aug 2015 | B2 |
9103823 | Elsemore et al. | Aug 2015 | B2 |
9134303 | Koulchin et al. | Sep 2015 | B1 |
9139642 | Williamson et al. | Sep 2015 | B2 |
9140693 | Ewart et al. | Sep 2015 | B2 |
9145458 | Bedinger et al. | Sep 2015 | B2 |
9150644 | Dimitrov et al. | Oct 2015 | B2 |
9150846 | Jefferies et al. | Oct 2015 | B2 |
9151747 | Parente | Oct 2015 | B1 |
9161992 | Jefferies et al. | Oct 2015 | B2 |
9164087 | Chan | Oct 2015 | B2 |
9176033 | Angros | Nov 2015 | B2 |
9193795 | Williams | Nov 2015 | B2 |
9199234 | Wang et al. | Dec 2015 | B2 |
9200324 | Cavet et al. | Dec 2015 | B2 |
9201065 | Ruddell et al. | Dec 2015 | B2 |
9201078 | Wang et al. | Dec 2015 | B2 |
9207181 | Egan et al. | Dec 2015 | B2 |
9212220 | Elsemore et al. | Dec 2015 | B2 |
9222119 | Heller et al. | Dec 2015 | B2 |
9222936 | Schwartz et al. | Dec 2015 | B2 |
9239284 | Livingston | Jan 2016 | B2 |
9239326 | Geng et al. | Jan 2016 | B2 |
20010051717 | Wakshull et al. | Dec 2001 | A1 |
20020031786 | Romaschin et al. | Mar 2002 | A1 |
20020045195 | Hubscher | Apr 2002 | A1 |
20020090632 | Buck, Jr. et al. | Jul 2002 | A1 |
20020095073 | Jacobs et al. | Jul 2002 | A1 |
20020115062 | Fletcher et al. | Aug 2002 | A1 |
20020177165 | Ashkenazi et al. | Nov 2002 | A1 |
20030017075 | Angros | Jan 2003 | A1 |
20030032057 | Ashkenazi et al. | Feb 2003 | A1 |
20030032062 | Ashkenazi et al. | Feb 2003 | A1 |
20030032063 | Ashkenazi et al. | Feb 2003 | A1 |
20030040014 | Ashkenazi et al. | Feb 2003 | A1 |
20030044844 | Ashkenazi et al. | Mar 2003 | A1 |
20030044902 | Ashkenazi et al. | Mar 2003 | A1 |
20030049857 | Chan | Mar 2003 | A1 |
20030069178 | Ashkenazi et al. | Apr 2003 | A1 |
20030073129 | Baker et al. | Apr 2003 | A1 |
20030073149 | Archer et al. | Apr 2003 | A1 |
20030077583 | Ashkenazi et al. | Apr 2003 | A1 |
20030083248 | Ashkenazi et al. | May 2003 | A1 |
20030083462 | Baker et al. | May 2003 | A1 |
20030109420 | Valkirs et al. | Jun 2003 | A1 |
20030113718 | Ashkenazi et al. | Jun 2003 | A1 |
20030119097 | Baker et al. | Jun 2003 | A1 |
20030129186 | Beliveau et al. | Jul 2003 | A1 |
20030143652 | Simonson | Jul 2003 | A1 |
20030153019 | Das et al. | Aug 2003 | A1 |
20030170144 | Angros | Sep 2003 | A1 |
20030170721 | Ashkenazi et al. | Sep 2003 | A1 |
20030180796 | Ashkenazi et al. | Sep 2003 | A1 |
20030180836 | Baker et al. | Sep 2003 | A1 |
20030186318 | Baker et al. | Oct 2003 | A1 |
20030187192 | Baker et al. | Oct 2003 | A1 |
20030191299 | Baker et al. | Oct 2003 | A1 |
20030216561 | Ashkenazi et al. | Nov 2003 | A1 |
20030220471 | Baker et al. | Nov 2003 | A1 |
20030220475 | Fields et al. | Nov 2003 | A1 |
20030224452 | Colgin et al. | Dec 2003 | A1 |
20030224471 | Jones et al. | Dec 2003 | A1 |
20030235877 | Kohl et al. | Dec 2003 | A1 |
20040006219 | Ashkenazi et al. | Jan 2004 | A1 |
20040053342 | Romaschin et al. | Mar 2004 | A1 |
20040072241 | Valkirs et al. | Apr 2004 | A1 |
20040116350 | Wentworth, Jr. et al. | Jun 2004 | A1 |
20040121480 | Wei et al. | Jun 2004 | A1 |
20040132106 | Houthoff et al. | Jul 2004 | A1 |
20040146516 | Roben et al. | Jul 2004 | A1 |
20040157262 | Kohl et al. | Aug 2004 | A1 |
20040176270 | Chen et al. | Sep 2004 | A1 |
20040214244 | Tonelli et al. | Oct 2004 | A1 |
20040229214 | Fields et al. | Nov 2004 | A1 |
20040265924 | Hollyfield et al. | Dec 2004 | A1 |
20050026823 | Zankel et al. | Feb 2005 | A1 |
20050042227 | Zankel et al. | Feb 2005 | A1 |
20050053526 | Angros | Mar 2005 | A1 |
20050054079 | Angros | Mar 2005 | A1 |
20050054080 | Angros | Mar 2005 | A1 |
20050085630 | Olejnik et al. | Apr 2005 | A1 |
20050096485 | Scanlan et al. | May 2005 | A1 |
20050112700 | Perez et al. | May 2005 | A1 |
20050112703 | Song | May 2005 | A1 |
20050112785 | Wong et al. | May 2005 | A1 |
20050130207 | Hainfeld et al. | Jun 2005 | A1 |
20050130243 | Zheng et al. | Jun 2005 | A1 |
20050163774 | Rosenblum et al. | Jul 2005 | A1 |
20050170362 | Wada et al. | Aug 2005 | A1 |
20050191620 | McDevitt et al. | Sep 2005 | A1 |
20050191694 | Jacobs et al. | Sep 2005 | A1 |
20050191762 | Staples et al. | Sep 2005 | A1 |
20050239116 | Willey | Oct 2005 | A1 |
20050255527 | Yang et al. | Nov 2005 | A1 |
20050255533 | Dantini et al. | Nov 2005 | A1 |
20050272798 | Ng et al. | Dec 2005 | A1 |
20050281833 | Singh et al. | Dec 2005 | A1 |
20060004081 | Chen et al. | Jan 2006 | A1 |
20060013860 | Ng et al. | Jan 2006 | A1 |
20060024317 | Boyd et al. | Feb 2006 | A1 |
20060029586 | Chen et al. | Feb 2006 | A1 |
20060029609 | Zankel et al. | Feb 2006 | A1 |
20060035980 | Scanlan et al. | Feb 2006 | A1 |
20060040408 | Jones et al. | Feb 2006 | A1 |
20060051237 | Wang et al. | Mar 2006 | A1 |
20060051824 | An et al. | Mar 2006 | A1 |
20060063204 | Valkirs et al. | Mar 2006 | A1 |
20060073474 | Perez et al. | Apr 2006 | A1 |
20060084184 | Hu et al. | Apr 2006 | A1 |
20060160134 | Melker et al. | Jul 2006 | A1 |
20060177873 | Dowd et al. | Aug 2006 | A1 |
20060194267 | Vojdani | Aug 2006 | A1 |
20060204999 | MacEvicz | Sep 2006 | A1 |
20060205087 | Feaster et al. | Sep 2006 | A1 |
20060217322 | Bricker et al. | Sep 2006 | A1 |
20060240453 | Jacobs et al. | Oct 2006 | A1 |
20060246526 | Inganas et al. | Nov 2006 | A1 |
20060247295 | Gangwar et al. | Nov 2006 | A1 |
20060257866 | Welch et al. | Nov 2006 | A1 |
20060257941 | McDevitt et al. | Nov 2006 | A1 |
20060275841 | Blankfard et al. | Dec 2006 | A1 |
20060275846 | Dorval et al. | Dec 2006 | A1 |
20070031283 | Davis et al. | Feb 2007 | A1 |
20070048746 | Su et al. | Mar 2007 | A1 |
20070054317 | Diebold et al. | Mar 2007 | A1 |
20070072241 | Hollyfield et al. | Mar 2007 | A1 |
20070092517 | Chang et al. | Apr 2007 | A1 |
20070099213 | Pompejus et al. | May 2007 | A1 |
20070104709 | Li et al. | May 2007 | A1 |
20070141658 | Chang | Jun 2007 | A1 |
20070154970 | Buechler et al. | Jul 2007 | A1 |
20070167365 | Beliveau et al. | Jul 2007 | A1 |
20070184492 | Wang et al. | Aug 2007 | A1 |
20070184495 | Shaari | Aug 2007 | A1 |
20070196867 | Mancebo et al. | Aug 2007 | A1 |
20070231889 | Angros | Oct 2007 | A1 |
20070232556 | Montine et al. | Oct 2007 | A1 |
20070254285 | Zhelev et al. | Nov 2007 | A1 |
20070259376 | Yoshimura | Nov 2007 | A1 |
20070269902 | Beechem et al. | Nov 2007 | A1 |
20070275427 | Akimoto et al. | Nov 2007 | A1 |
20080003626 | White et al. | Jan 2008 | A1 |
20080014659 | Wei et al. | Jan 2008 | A1 |
20080015465 | Scuderi | Jan 2008 | A1 |
20080021196 | Tang et al. | Jan 2008 | A1 |
20080032417 | Olejnik et al. | Feb 2008 | A1 |
20080064113 | Goix et al. | Mar 2008 | A1 |
20080090253 | Song | Apr 2008 | A1 |
20080096225 | Vale et al. | Apr 2008 | A1 |
20080108101 | Miyazaki | May 2008 | A1 |
20080112946 | Koelsch et al. | May 2008 | A1 |
20080118944 | Larsen et al. | May 2008 | A1 |
20080124747 | Valkirs et al. | May 2008 | A1 |
20080153092 | Kienle et al. | Jun 2008 | A1 |
20080160499 | Grenier et al. | Jul 2008 | A1 |
20080160505 | Hollyfield et al. | Jul 2008 | A1 |
20080166745 | Khan et al. | Jul 2008 | A1 |
20080171352 | Goix et al. | Jul 2008 | A1 |
20080181879 | Catelas et al. | Jul 2008 | A1 |
20080182262 | Perez et al. | Jul 2008 | A1 |
20080199887 | Valdez et al. | Aug 2008 | A1 |
20080202933 | Hu | Aug 2008 | A1 |
20080248504 | Ruddell et al. | Oct 2008 | A1 |
20080254489 | Perez et al. | Oct 2008 | A1 |
20080261889 | Vanmechelen et al. | Oct 2008 | A1 |
20080262989 | Su et al. | Oct 2008 | A1 |
20080279868 | Boyd et al. | Nov 2008 | A1 |
20080305559 | Gonzalez-Sapienza et al. | Dec 2008 | A1 |
20080311557 | Elsemore et al. | Dec 2008 | A1 |
20080311600 | Elsemore et al. | Dec 2008 | A1 |
20080318305 | Angros | Dec 2008 | A1 |
20090005260 | Su et al. | Jan 2009 | A1 |
20090042206 | Schneider et al. | Feb 2009 | A1 |
20090061535 | Dowd et al. | Mar 2009 | A1 |
20090068635 | Muerhoff et al. | Mar 2009 | A1 |
20090068679 | Vitzthum et al. | Mar 2009 | A1 |
20090068681 | Perez et al. | Mar 2009 | A1 |
20090075881 | Catelas et al. | Mar 2009 | A1 |
20090081638 | Bergwerff et al. | Mar 2009 | A1 |
20090081699 | Perez et al. | Mar 2009 | A1 |
20090093069 | Valdez et al. | Apr 2009 | A1 |
20090104170 | Childs et al. | Apr 2009 | A1 |
20090105347 | Scanlan et al. | Apr 2009 | A1 |
20090111088 | Martin et al. | Apr 2009 | A1 |
20090148858 | Patel et al. | Jun 2009 | A1 |
20090152114 | Kawabata et al. | Jun 2009 | A1 |
20090155850 | Almagro et al. | Jun 2009 | A1 |
20090159812 | Livingston | Jun 2009 | A1 |
20090175888 | Ng et al. | Jul 2009 | A1 |
20090181410 | Hsieh | Jul 2009 | A1 |
20090208451 | Smider et al. | Aug 2009 | A1 |
20090208960 | Kelly et al. | Aug 2009 | A1 |
20090209734 | Ng et al. | Aug 2009 | A1 |
20090214554 | Chang et al. | Aug 2009 | A1 |
20090220993 | Turecek et al. | Sep 2009 | A1 |
20090221100 | Weber et al. | Sep 2009 | A1 |
20090221433 | Barnes et al. | Sep 2009 | A1 |
20090233319 | Katagiri et al. | Sep 2009 | A1 |
20090251683 | Wardlaw et al. | Oct 2009 | A1 |
20090270599 | Angros | Oct 2009 | A1 |
20090275142 | Huang et al. | Nov 2009 | A1 |
20090286227 | Elsemore et al. | Nov 2009 | A1 |
20090286228 | Elsemore et al. | Nov 2009 | A1 |
20090286229 | Elsemore et al. | Nov 2009 | A1 |
20090286230 | Elsemore et al. | Nov 2009 | A1 |
20090286231 | Elsemore et al. | Nov 2009 | A1 |
20090289182 | Pevsner | Nov 2009 | A1 |
20090297438 | Huang et al. | Dec 2009 | A1 |
20090305306 | Stahl et al. | Dec 2009 | A1 |
20090311260 | Goddard et al. | Dec 2009 | A1 |
20090311261 | Goddard et al. | Dec 2009 | A1 |
20090314946 | Song et al. | Dec 2009 | A1 |
20090325198 | Holets-McCormack | Dec 2009 | A1 |
20090325276 | Battrell et al. | Dec 2009 | A1 |
20100009429 | Angros | Jan 2010 | A1 |
20100021457 | Pfleger et al. | Jan 2010 | A1 |
20100022029 | Yoshimura | Jan 2010 | A1 |
20100034699 | Chan | Feb 2010 | A1 |
20100034817 | Abbas et al. | Feb 2010 | A1 |
20100035234 | Donnelly et al. | Feb 2010 | A1 |
20100035274 | Murthy et al. | Feb 2010 | A1 |
20100055033 | Dimitrov et al. | Mar 2010 | A1 |
20100068096 | Angros | Mar 2010 | A1 |
20100068102 | Angros | Mar 2010 | A1 |
20100068135 | Rock | Mar 2010 | A1 |
20100092496 | Boyd et al. | Apr 2010 | A1 |
20100092999 | Bricker et al. | Apr 2010 | A1 |
20100098684 | Scuderi et al. | Apr 2010 | A1 |
20100113476 | Chen et al. | May 2010 | A1 |
20100130402 | Pfuetzner et al. | May 2010 | A1 |
20100144543 | Witcher et al. | Jun 2010 | A1 |
20100151500 | Geng et al. | Jun 2010 | A1 |
20100173797 | Jacobs et al. | Jul 2010 | A1 |
20100183581 | Beliveau et al. | Jul 2010 | A1 |
20100184087 | Kosmeder et al. | Jul 2010 | A1 |
20100196207 | Steinmiller et al. | Aug 2010 | A1 |
20100221272 | Napper et al. | Sep 2010 | A1 |
20100221750 | Perez et al. | Sep 2010 | A1 |
20100233741 | Wang et al. | Sep 2010 | A1 |
20100235930 | Shaw et al. | Sep 2010 | A1 |
20100247571 | Wong | Sep 2010 | A1 |
20100248217 | Elsemore et al. | Sep 2010 | A1 |
20100248273 | Campbell et al. | Sep 2010 | A1 |
20100279432 | Muerhoff et al. | Nov 2010 | A1 |
20100323343 | Egan | Dec 2010 | A1 |
20100323369 | Marlborough et al. | Dec 2010 | A1 |
20100329929 | Goix et al. | Dec 2010 | A1 |
20100330591 | Mancebo et al. | Dec 2010 | A1 |
20110020839 | Perez et al. | Jan 2011 | A1 |
20110039278 | Pieribone | Feb 2011 | A1 |
20110053161 | Hong et al. | Mar 2011 | A1 |
20110053171 | Gerdes et al. | Mar 2011 | A1 |
20110065127 | Heller et al. | Mar 2011 | A1 |
20110076268 | Williamson et al. | Mar 2011 | A1 |
20110076701 | Dodds | Mar 2011 | A1 |
20110086340 | Elsemore et al. | Apr 2011 | A1 |
20110097735 | Mao et al. | Apr 2011 | A1 |
20110111415 | Dodds | May 2011 | A1 |
20110111425 | Rylatt et al. | May 2011 | A1 |
20110130306 | Chang | Jun 2011 | A1 |
20110136099 | Schneider et al. | Jun 2011 | A1 |
20110137851 | Cavet et al. | Jun 2011 | A1 |
20110142763 | Zankel et al. | Jun 2011 | A1 |
20110143351 | Rudd et al. | Jun 2011 | A1 |
20110171662 | Grenier et al. | Jul 2011 | A1 |
20110177529 | Shaari | Jul 2011 | A1 |
20110177534 | Salant et al. | Jul 2011 | A1 |
20110184747 | Bozic et al. | Jul 2011 | A1 |
20110189084 | Zankel | Aug 2011 | A1 |
20110189166 | Boucher | Aug 2011 | A1 |
20110201018 | Perez et al. | Aug 2011 | A1 |
20110207149 | Perez et al. | Aug 2011 | A1 |
20110223683 | Regnier et al. | Sep 2011 | A1 |
20110229905 | Kimchi et al. | Sep 2011 | A1 |
20110245090 | Abbas et al. | Oct 2011 | A1 |
20110250614 | Perez et al. | Oct 2011 | A1 |
20110263043 | Livingston | Oct 2011 | A1 |
20110269159 | Campbell et al. | Nov 2011 | A1 |
20110269634 | Perez et al. | Nov 2011 | A1 |
20110294140 | Holets-McCormack | Dec 2011 | A1 |
20110294200 | Wardlaw et al. | Dec 2011 | A1 |
20110311522 | Chen | Dec 2011 | A1 |
20110312085 | Angros | Dec 2011 | A1 |
20110312531 | Jacobs et al. | Dec 2011 | A1 |
20110318825 | Angros | Dec 2011 | A1 |
20120009666 | Gerdes et al. | Jan 2012 | A1 |
20120015376 | Bornhop | Jan 2012 | A1 |
20120028280 | Bricker et al. | Feb 2012 | A1 |
20120034160 | Ghayur et al. | Feb 2012 | A1 |
20120058570 | Angros | Mar 2012 | A1 |
20120065095 | Kienle et al. | Mar 2012 | A1 |
20120070849 | Perez et al. | Mar 2012 | A1 |
20120073969 | Campbell et al. | Mar 2012 | A1 |
20120087831 | Chan | Apr 2012 | A1 |
20120087858 | Ghayur et al. | Apr 2012 | A1 |
20120088689 | Mayer et al. | Apr 2012 | A1 |
20120107198 | Angros | May 2012 | A1 |
20120122129 | Shaari | May 2012 | A1 |
20120125788 | Diebold et al. | May 2012 | A1 |
20120129190 | Chiu et al. | May 2012 | A1 |
20120156693 | Wong et al. | Jun 2012 | A1 |
20120203465 | Callewaert et al. | Aug 2012 | A1 |
20120208983 | Elsemore et al. | Aug 2012 | A1 |
20120225438 | Passavant et al. | Sep 2012 | A1 |
20120237401 | Steinmiller et al. | Sep 2012 | A1 |
20120276548 | Schmidt | Nov 2012 | A1 |
20120301896 | Wang et al. | Nov 2012 | A1 |
20120301905 | Wang et al. | Nov 2012 | A1 |
20120301906 | Collier et al. | Nov 2012 | A1 |
20120309026 | Perez et al. | Dec 2012 | A1 |
20120329176 | Muerhoff et al. | Dec 2012 | A1 |
20130040286 | Chan | Feb 2013 | A1 |
20130052748 | Campbell et al. | Feb 2013 | A1 |
20130059400 | Livingston | Mar 2013 | A1 |
20130065324 | Mitchell et al. | Mar 2013 | A1 |
20130084585 | Stridsberg et al. | Apr 2013 | A1 |
20130122518 | Callewaert et al. | May 2013 | A1 |
20130130285 | Atkinson et al. | May 2013 | A1 |
20130130366 | Angros | May 2013 | A1 |
20130137598 | Verschoor et al. | May 2013 | A1 |
20130137607 | Ghatak | May 2013 | A1 |
20130137632 | Pfuetzner et al. | May 2013 | A1 |
20130137748 | Hamamoto et al. | May 2013 | A1 |
20130149694 | Elsemore et al. | Jun 2013 | A1 |
20130153420 | Hu | Jun 2013 | A1 |
20130157295 | Bricker et al. | Jun 2013 | A1 |
20130157381 | Pang et al. | Jun 2013 | A1 |
20130164739 | Heemstra | Jun 2013 | A1 |
20130165332 | Abbas et al. | Jun 2013 | A1 |
20130177970 | Perez et al. | Jul 2013 | A1 |
20130184188 | Ewart et al. | Jul 2013 | A1 |
20130189797 | Quinn | Jul 2013 | A1 |
20130210669 | Pieribone | Aug 2013 | A1 |
20130213822 | Diebold et al. | Aug 2013 | A1 |
20130217146 | Wardlaw et al. | Aug 2013 | A1 |
20130224759 | Elsemore et al. | Aug 2013 | A1 |
20130230844 | Egan et al. | Sep 2013 | A1 |
20130252245 | Micallef et al. | Sep 2013 | A1 |
20130252321 | Steinmiller et al. | Sep 2013 | A1 |
20130261023 | Barnes et al. | Oct 2013 | A1 |
20130267010 | Wang et al. | Oct 2013 | A1 |
20130273576 | Campbell et al. | Oct 2013 | A1 |
20130280738 | Salant et al. | Oct 2013 | A1 |
20130280740 | Yerramilli et al. | Oct 2013 | A1 |
20130281660 | Heller et al. | Oct 2013 | A1 |
20130284942 | Livingston | Oct 2013 | A1 |
20130288347 | Livingston | Oct 2013 | A1 |
20130288388 | Freeby et al. | Oct 2013 | A1 |
20130309661 | Bomhop | Nov 2013 | A1 |
20130344508 | Schwartz et al. | Dec 2013 | A1 |
20140004506 | Song | Jan 2014 | A1 |
20140024024 | Sood et al. | Jan 2014 | A1 |
20140024057 | Passavant et al. | Jan 2014 | A1 |
20140065722 | Goix et al. | Mar 2014 | A1 |
20140072989 | Collier et al. | Mar 2014 | A1 |
20140093893 | Angros | Apr 2014 | A1 |
20140170068 | Thiele et al. | Jun 2014 | A1 |
20140170682 | Pevsner | Jun 2014 | A1 |
20140170684 | Elsemore et al. | Jun 2014 | A1 |
20140178899 | Kimchi et al. | Jun 2014 | A1 |
20140178904 | Zimring | Jun 2014 | A1 |
20140186934 | Chan | Jul 2014 | A1 |
20140193332 | Goddard et al. | Jul 2014 | A1 |
20140205994 | Elsemore et al. | Jul 2014 | A1 |
20140206020 | Valdez et al. | Jul 2014 | A1 |
20140219912 | Ghayur et al. | Aug 2014 | A1 |
20140220019 | Ghayur et al. | Aug 2014 | A1 |
20140227714 | Angros | Aug 2014 | A1 |
20140234208 | Ghayur et al. | Aug 2014 | A1 |
20140234340 | Igawa et al. | Aug 2014 | A1 |
20140242720 | Nishida et al. | Aug 2014 | A1 |
20140242723 | Yerramilli et al. | Aug 2014 | A1 |
20140249043 | Schneider et al. | Sep 2014 | A1 |
20140287431 | Hibino et al. | Sep 2014 | A1 |
20140294850 | Ronco et al. | Oct 2014 | A1 |
20140302509 | Moerman et al. | Oct 2014 | A1 |
20140303023 | Mayer et al. | Oct 2014 | A1 |
20140303033 | Ehricht et al. | Oct 2014 | A1 |
20140308168 | Steinmiller et al. | Oct 2014 | A1 |
20140323336 | Kosmeder, II et al. | Oct 2014 | A1 |
20140323347 | Ghatak | Oct 2014 | A1 |
20140323545 | Garcia | Oct 2014 | A1 |
20140329705 | Wong et al. | Nov 2014 | A1 |
20140342380 | Saal | Nov 2014 | A1 |
20140349318 | Pevsner | Nov 2014 | A1 |
20140360878 | Paulus et al. | Dec 2014 | A1 |
20140371086 | Abbas et al. | Dec 2014 | A1 |
20150011018 | Pieribone | Jan 2015 | A1 |
20150024456 | Valdez et al. | Jan 2015 | A1 |
20150030504 | Pang et al. | Jan 2015 | A1 |
20150031581 | Kema et al. | Jan 2015 | A1 |
20150056687 | Tyrrell | Feb 2015 | A1 |
20150072352 | Heemstra | Mar 2015 | A1 |
20150072359 | Stubenrauch et al. | Mar 2015 | A1 |
20150094449 | Heller et al. | Apr 2015 | A1 |
20150099650 | Sood et al. | Apr 2015 | A1 |
20150105280 | Regnier et al. | Apr 2015 | A1 |
20150108367 | Livingston | Apr 2015 | A1 |
20150140001 | Lee et al. | May 2015 | A1 |
20150160217 | Wong et al. | Jun 2015 | A1 |
20150169840 | Kupfer et al. | Jun 2015 | A1 |
20150192576 | Manez Mendiluce | Jul 2015 | A1 |
20150196908 | Steinmiller et al. | Jul 2015 | A9 |
20150219635 | Lawson et al. | Aug 2015 | A1 |
20150219639 | Pfuetzner et al. | Aug 2015 | A1 |
20150226732 | De Theije et al. | Aug 2015 | A1 |
20150241442 | Nolan et al. | Aug 2015 | A1 |
20150260718 | Elsemore et al. | Sep 2015 | A1 |
20150276732 | Campbell et al. | Oct 2015 | A1 |
20150299308 | Vitzthum et al. | Oct 2015 | A1 |
20150301050 | Wang et al. | Oct 2015 | A1 |
20150301058 | Schettini et al. | Oct 2015 | A1 |
20150338396 | Narimatsu et al. | Nov 2015 | A1 |
20150355172 | Kraus et al. | Dec 2015 | A1 |
20150369815 | Micallef et al. | Dec 2015 | A1 |
20150377909 | Cavet et al. | Dec 2015 | A1 |
Number | Date | Country |
---|---|---|
19502375 | Aug 1996 | DE |
19502375 | Jun 2000 | DE |
0122059 | Oct 1984 | EP |
0125118 | Nov 1984 | EP |
0160467 | Nov 1985 | EP |
0199261 | Oct 1986 | EP |
0212670 | Mar 1987 | EP |
0231010 | Aug 1987 | EP |
0475783 | Mar 1992 | EP |
1847610 | Oct 2007 | EP |
1947183 | Jul 2008 | EP |
1961293 | Aug 2008 | EP |
1980573 | Oct 2008 | EP |
1985630 | Oct 2008 | EP |
2003451 | Dec 2008 | EP |
2020239 | Feb 2009 | EP |
2052742 | Apr 2009 | EP |
2113566 | Nov 2009 | EP |
2153848 | Feb 2010 | EP |
2172478 | Apr 2010 | EP |
2258726 | Dec 2010 | EP |
2261256 | Dec 2010 | EP |
2266986 | Dec 2010 | EP |
2275447 | Jan 2011 | EP |
2293067 | Mar 2011 | EP |
2298802 | Mar 2011 | EP |
2316974 | May 2011 | EP |
2327985 | Jun 2011 | EP |
2333113 | Jun 2011 | EP |
2354163 | Aug 2011 | EP |
2381256 | Oct 2011 | EP |
2389943 | Nov 2011 | EP |
2399586 | Dec 2011 | EP |
2416157 | Feb 2012 | EP |
2423201 | Feb 2012 | EP |
2436774 | Apr 2012 | EP |
2453024 | May 2012 | EP |
2479578 | Jul 2012 | EP |
2511266 | Oct 2012 | EP |
2564864 | Mar 2013 | EP |
2605015 | Jun 2013 | EP |
2712620 | Apr 2014 | EP |
2757091 | Jul 2014 | EP |
2902036 | Aug 2015 | EP |
2942357 | Nov 2015 | EP |
2204398 | Nov 1988 | GB |
WO8402193 | Jun 1984 | WO |
WO8908258 | Sep 1989 | WO |
WO9001564 | Feb 1990 | WO |
WO9106007 | May 1991 | WO |
WO9108480 | Jun 1991 | WO |
WO9306487 | Apr 1993 | WO |
WO9401768 | Jan 1994 | WO |
WO9532414 | Nov 1995 | WO |
WO9804743 | Feb 1998 | WO |
WO0125788 | Apr 2001 | WO |
WO03057179 | Jul 2003 | WO |
WO03065002 | Aug 2003 | WO |
WO2005002515 | Jan 2005 | WO |
WO2005077093 | Aug 2005 | WO |
WO2007035716 | Mar 2007 | WO |
WO2007038658 | Apr 2007 | WO |
WO2007056352 | May 2007 | WO |
WO2008020293 | Feb 2008 | WO |
WO2008118324 | Oct 2008 | WO |
WO2010065867 | Jun 2010 | WO |
WO2011020079 | Feb 2011 | WO |
WO2011035205 | Mar 2011 | WO |
WO2011056997 | May 2011 | WO |
WO2011094536 | Aug 2011 | WO |
WO2011156759 | Dec 2011 | WO |
WO2012006596 | Jan 2012 | WO |
WO2012012718 | Jan 2012 | WO |
WO2012092323 | Jul 2012 | WO |
WO2012099897 | Jul 2012 | WO |
WO2012149047 | Nov 2012 | WO |
WO2013007839 | Jan 2013 | WO |
WO2013022738 | Feb 2013 | WO |
WO2013111054 | Aug 2013 | WO |
WO2014012077 | Jan 2014 | WO |
WO2014015076 | Jan 2014 | WO |
WO2015038978 | Mar 2015 | WO |